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 Cigarette smoke is well recognized to cause injury to the airways and the alveolar 
walls over time. This injury usually requires many years of exposure, suggesting that the 
lungs may rapidly develop responses that initially protect it from this repetitive injury. Our 
studies tested the hypotheses that smoke induces changes in mRNA profiles that are 
dependent on sex and the health status of the lung, and that the effects of smoke are different 
after 1 day compared to 5 days of exposure. Male and female wild type (WT) and Scnn1b-
transgenic (bENaC) mice, which have chronic bronchitis and emphysematous changes due to 
dehydrated mucus, were exposed to cigarette smoke or sham air conditions for 1 or 5 days. 
Gene expression from lung tissue was analyzed. Overall, the response to cigarette smoke is 
similar at 1 compared to 5 days. Many genes and gene sets responded similarly: genes 
involved in oxidative stress responses were consistently upregulated while genes involved in 
the immune response were consistently downregulated. However, certain genes and 
biological processes were regulated differently after 1 compared to 5 days. Extracellular 
matrix biology genes and gene sets were upregulated after 1 day but downregulated by 5 
days of smoke compared to sham exposure. By contrast, there was no difference in the 
response to smoke between WT and βENaC mice and between male and female mice at 
either 1 or 5 days, suggesting sex and genotype affect gene expression independently from 
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smoke. Taken together, these studies suggest that the lungs rapidly alter gene expression after 
only one exposure to cigarette smoke, with few additional changes after four more days of 
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Chapter 1: Introduction – The Acute Effects of Cigarette Smoke on the Murine Lung and 
How that Response Corresponds to Cigarette Smoke-induced Lung Disease in Humans 
1.1. Overview 
Cigarette smoke is a leading health hazard and causes an enormous impact on lung 
health. Cigarette smoking has long been known to have a significant impact on respiratory health 
and diseases [1, 2]. Smoking is the number one cause of lung cancer and chronic obstructive 
pulmonary disease, and it increases the odds of developing either chronic bronchitis or 
emphysema [2, 3]. More than 16 million Americans are currently living with a tobacco smoke-
related disease, resulting in nearly $170 billion in direct healthcare costs annually [2, 4].    
The response of the lungs to the first exposure of cigarette smoke and how this response 
changes following subsequent exposures is important for understanding tobacco-induced lung 
injury and is nearly impossible to study in humans. Compared to a single stimulus, the lung’s 
response to repeated exposures of a stimulus such as endotoxin shows evidence of adaptation or 
tolerance [5], particularly when the stimulus induces oxidative stress in epithelial and immune 
cells [6]. The effect of a single exposure to cigarette smoke on gene expression in the lungs has 
not been evaluated. Most interesting are questions about changes that occur in response to a 
single dose of cigarette smoke compared to changes resulting from consecutive repeated 
exposures. The changes in gene expression, and particularly in pathways regulating host defense, 
can be used to evaluate how the lung adapts to cigarette smoke exposure.  
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Additionally, many mouse models of smoking use acute exposure durations of fewer than 
5 consecutive days of cigarette smoke exposure [7, 8]. Understanding how the lungs cope with 
the oxidant burden and the many gaseous and particulate components of cigarette smoke initially 
and upon repeated exposures is likely to provide information about pathways and processes 
underlying host defense and the development of chronic lung disease.  
The response of the lungs to the first exposure of cigarette smoke and how this response 
changes following subsequent exposures is important for understanding tobacco-induced lung 
injury and is nearly impossible to study in humans. Compared to a single stimulus, the lung’s 
response to repeated exposures of a stimulus such as endotoxin shows evidence of adaptation or 
tolerance [5], particularly when the stimulus induces oxidative stress in epithelial and immune 
cells [6]. The effect of a single exposure to cigarette smoke on gene expression in the lungs has 
not been evaluated. Most interesting are questions about changes that occur in response to a 
single dose of cigarette smoke compared to changes resulting from consecutive repeated 
exposures. The changes in gene expression, and particularly in pathways regulating host defense, 
can be used to evaluate how the lung adapts to cigarette smoke exposure. Additionally, many 
mouse models of smoking use acute exposure durations of fewer than 5 consecutive days of 
cigarette smoke exposure [7, 8]. Understanding how the lungs cope with the oxidant burden and 
the many gaseous and particulate components of cigarette smoke initially and upon repeated 
exposures is likely to provide information about pathways and processes underlying host defense 
and the development of chronic lung disease.  
Males and females differ in their response to smoke exposure and the development of 
tobacco smoke-associated disease [2, 3]. Although this sex difference has been shown in humans 
who are chronic smokers, no studies investigate sex differences at early time points after 
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initiation of smoking in humans. Additionally, to the best of our knowledge, no publication has 
assessed the effects of sex on the response of the lungs to acute smoke exposure in a mouse 
model to date. Given the differences in smoking-related lung disease incidence and pathology in 
humans, this is an important research question to pursue [9-15]. Understanding how sex impacts 
the development and initiation of tobacco smoke-related disease is important for developing 
treatment protocols for patients.  
These studies tested the hypotheses that smoke induces changes in mRNA profiles that 
are dependent on sex and the health status of the lung, and that the effects of smoke are different 
after 1 day compared to 5 days of exposure. The changes over time during increasing acute 
exposure durations are likely to provide insight into the mechanisms important in protection 
against smoke-induced lung damage. 
1.1. Gene Expression Changes in Response to Cigarette Smoke Exposure  
Cigarette smoke exposure has a lasting effect on gene expression and regulation in the 
lung and systemically. Former smokers who have not smoked for decades continue to have an 
increased risk for COPD, among other diseases [2]. Changes in DNA methylation in blood-
derived DNA samples at 185 sites across the genome between former smokers and non-smokers, 
which are also changed in current smokers, have been proposed to account for that increased risk 
after smoking cessation [16]. Furthermore, hundreds of differentially-expressed long noncoding 
RNAs (lncRNAs) have been identified as differentially expressed in lung tissue in response to 
cigarette smoke when comparing healthy smokers and non-smokers. These lncRNAs were 
associated with the activation of metabolic pathways. A different set of lncRNAs distinguished 
healthy smokers from smokers with COPD and were enriched in immune system processes [17].  
	 	
4 
Mouse models are particularly useful for investigating the specific role of particular 
smoke-responsive genes in the lung’s adaptation to cigarette smoke and the ensuing 
inflammatory state and lung disease. For example, one study investigated the role of Fra-1, a 
transcription factor regulating inflammation and immune responses, and known to be 
upregulated in response to cigarette smoke. Using Fra-1 knockout mice and Fra-1-null 
macrophages, the group determined that Fra-1 regulates cigarette smoke-induced lung 
inflammation specifically, and did not play a role in the severity of chronic smoke-induced 
emphysema [18].  
Alveolar macrophages (AMs) have a well-documented role in cigarette smoke-induced 
lung disease, although their role in pathogenesis versus progression is still hotly debated [19-30]. 
The quantity of macrophages present in the lung tissue of patients with COPD is increased, and 
the magnitude is correlated with the severity of COPD stage [26, 31-33]. It has been well 
documented that the antimicrobial activity of AMs in both healthy smokers and smokers with 
COPD is impaired, [20, 27] which is predicted to contribute to the increased susceptibility to 
respiratory infections in smokers [34].    
In the alveolar macrophages of human smokers, there are global differences in both 
mRNA and miRNA expression profiles. Overall, smokers experience a global decrease in the 
abundance of miRNAs in the alveolar macrophages, and the magnitude of depression appears to 
be related to the length of smoking history. Of the miRNAs that are expressed in AMs, there is a 
distinct expression profile from that of AMs in non-smokers. Several downregulated miRNAs 
were identified as targeting genes whose expression is upregulated in the AMs of smokers, such 
as miR-452 and its target gene encoding for MMP12 [23].  
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In a study profiling the gene expression of alveolar macrophages in human smokers and 
non-smokers, many genes were differentially expressed.  Genes coding for proteins belonging to 
varied biological pathways, including immune/inflammatory response, cell adhesion and 
extracellular matrix biology, proteolysis and antiproteolysis, lysosomal function, antioxidant 
response, signal transduction, and regulation of transcription were represented among the 
differentially expressed genes in alveolar macrophages [25]. The reprogramming of AMs 
through induction of tissue remodeling and immunoregulation genes after chronic smoke 
exposure increases further in patients with smoking-induced lung disease, such as COPD [29]. 
Genome-wide association studies of patients have identified several loci which influence 
the likelihood of developing chronic lung disease [35, 36]. Similarly, certain loci are associated 
with decreased lung disease only in the presence of cigarette smoke exposure [37].  These gene-
by-environment interactions represent a genetic predisposition to develop chronic lung disease 
only when the environmental conditions (cigarette smoke) are present. Genes involved in 
immune processes were identified, as well as novel genes such as SOX9 that have never been 
implicated in clinical lung function studies before [37]. The presence of these genetic markers 
identifies these patients as a sub-group within chronic lung disease patients, and presents the 
possibility for a therapeutic intervention based on these mechanisms of disease pathogenesis and 
progression.  
Certain sub-groups of smokers are destined to develop smoke-induced chronic lung 
disease, while others are destined to remain healthy, asymptomatic smokers. Identifying these 
sub-groups before their divergence and the presentation of symptoms would greatly enhance 
treatment potentials and increase quality of life. A combination of genetic susceptibility and 
time-dependent accumulation of damage to the lung tissue, among other processes, are predicted 
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to be the main factors influencing the stratification of patients into susceptible or resistant sub-
groups [38]. Together, these changes identify the transition model for COPD from a homeostatic 
state of chronic smoke exposure to smoke-induced chronic lung disease (also called the 
“toxicant-exposure-to-disease-transition model”). Induced sputum samples from patients with 
early-stage COPD, healthy smokers, former smokers, and nonsmokers were used to identify 
biomarkers of this transition through proteomics and transcriptome analysis. Both genes and 
proteins were identified as biomarkers of current smoking subjects, such as for ALDH3A1. 
Furthermore, current smokers with and without COPD showed similar changes in immune cell 
activation. However, between healthy smokers and smokers with COPD, only differences in 
protein level, not gene expression level, were found, including for TIMP1 and SERPINC1 [38]. 
1.2. How Murine Models of Cigarette Smoke Mimic Human Disease 
Mouse models are utilized for their similarity to the biological response in humans and 
increased genetic manipulability. Mouse models of cigarette smoke exposure reproduce many 
similar aspects of the human smoke-induced lung injury phenotype, including chronic smoke 
exposure-induced lung inflammation and disease.  
Gene expression in smoke-exposed mice reproduce many of the differentially expressed 
genes found in human smokers. For example, a panel of 11 genes developed by comparing gene 
expression in the blood of human smokers to non-smokers also successfully distinguished mice 
exposed to cigarette smoke from those exposed to sham exposure [39]. During a thorough 
comparison of whole-genome expression between mice and humans, similar pulmonary 
pathways and biological functions were significantly enriched, in addition to the list of genes 
[40]. The results replicated in humans and mice belong to three categories of biological 
processes: xenobiotics response/detoxification, phospholipids metabolism/degradation, and 
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oxidative stress defense/generation. The concordance observed between mice and human 
responses was stronger at the pathway level than when comparing individual genes across 
species, indicating that similar functional changes are occurring, but may be carried out by 
different genes. When comparing murine and human studies, different genes may perform the 
same function because they are homologous in their function.  
Further, alveolar macrophages in mouse models of emphysema recapitulate important 
differentially expressed genes found in the alveolar macrophages of human chronic smokers. For 
example, matrix metalloproteinase 12 (MMP12), a gene that contributes to the destruction of 
alveolar walls in chronic smoke-induced lung disease, was upregulated in all chronic smoker 
human subjects assayed as well as all transgenic emphysema mouse models surveyed. Several 
other genes were similarly changed in human smokers and at least one of the mouse models of 
emphysema [30]. Therefore, mouse models, even those without tobacco smoke as the cause of 
lung injury, recapitulate important aspects of the human smoke exposure response.  
Another study exposed four transgenic mouse lines (two susceptible to emphysema, and 
two resistant) to chronic (6 month) cigarette smoke exposure, and the results from the mouse 
lung gene expression were then compared to human smokers with and without COPD. The list of 
genes that responded similarly to cigarette smoke in all genotypes of smoke-exposed mice 
included classic xenobiotic metabolism and NRF2-mediated oxidative stress response genes. 
Many of the smoke response genes in mice were also found to be differentially expressed 
between healthy human smokers compared to non-smokers. Additionally, some genes were 
found to overlap with human COPD patients compared to healthy smokers [41].  
In humans, chronic lung disease, including that induced by tobacco smoke, causes an 
increased susceptibility to respiratory infections, such as nontypeable Haemophilus influenzae 
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(NTHi). A mouse model integrating both cigarette smoke exposure and chronic NTHi infection 
was designed to model the course of infection in humans – NTHi colonizes the airways when the 
patient is clinically stable, and later manifests in exacerbations. This mouse model showed 
increased pulmonary inflammation and compromised adaptive immunity via T cell recognition 
of the pathogen, thereby generating important hypotheses for exploration in clinical treatments 
for human patients [42]. A similar study utilized H1N1 viral infection in combination with 
cigarette smoke exposure in mice to model exacerbation episodes and was used to screen 
potential treatments for clinical patients [43]. 
1.3. Acute Cigarette Smoke Effects on the Murine Lung  
Acute cigarette smoke exposure protocols (defined here as 7 days or fewer of smoke 
exposure) are a cost-effective and informative model to explore the effects of cigarette smoke 
and identify potential chemokines and mediators that participate in the pathogenesis of cigarette 
smoke-induced lung inflammation. Several scholarly and review articles in the published 
literature delve deeply into this topic [7, 8, 44-47], which will be summarized here.  
Although mouse models of tobacco smoke-induced disease are useful for illuminating 
disease processes involved, there are some important caveats. Mice do not have a cough reflex, 
and therefore cannot fully recapitulate any of the human phenotypes involving chronic 
bronchitis. Additionally, mice are obligate nose breathers, which introduces additional filtering 
of aerosol particles before entering the respiratory system that is not consistently present in 
humans.  
Mouse models of acute cigarette smoke exposure (3 days) show the hallmark neutrophilic 
influx of lung injury and inflammatory cell recruitment to the alveolus [7], whereas a similar 
exposure length of sidestream-only smoke does not produce neutrophilic influx. In fact, in mice 
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exposed to 7 days of cigarette smoke or less, a neutrophilic influx accompanies the increase in 
BAL macrophages [22].  
In work from our lab, results from our experiments have suggested a sex difference in the 
recruitment of inflammatory cells to the BALF. BAL counts performed after acute (1-day) 
smoke or sham exposure showed that male smoke-exposed bENaC mice had more leukocytes 
than the corresponding female group. Interestingly, by 5 days of smoke exposure, the leukocytes 
in female bENaC smoke mice had increased to similar numbers as males, suggesting that the 
female response was delayed compared to the males. Thus, there appears to be a sex difference 
in the acute response to smoke.  
1.4. Sex Differences in the Response to Cigarette Smoke 
Cigarette smoking is associated with a serious burden to healthcare in our society because 
of the high prevalence of smoking-related chronic respiratory diseases [2]. A prime example of 
this is the increased prevalence of chronic obstructive pulmonary disease (COPD) among 
smokers [48, 49]. The number one risk factor for developing COPD is cigarette smoking. Since 
1950, more women have been diagnosed with COPD, purportedly due to the increase in smoking 
incidence[2]. However, women are diagnosed with worse disease despite having lower levels of 
cigarette smoke exposure with age- and exposure-matched males[50]. Additionally, more than 
80% of the 15-30% of patients diagnosed with COPD without any history of cigarette smoking 
are females[51].  COPD is characterized by a combination of chronic bronchitis and emphysema, 
which results in airflow obstruction and gas exchange abnormalities, respectively. Males and 
females experience disease progression differently: female smokers demonstrate faster declines 
in lung function after adjusting for smoking history and are more likely to be hospitalized [10, 
52, 53].   
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Animal models of tobacco smoke exposure are not often designed to ask questions about 
sex differences, but evidence suggests some sex differences in the lung’s response to smoke. An 
increase in small airway wall remodeling is observed in female mice, and there may be an earlier 
onset of cigarette smoke-induced emphysema in female mice, although that observation is not 
conclusive [19, 54-57].  
In human smokers, there is an increased number of circulating leukocytes in smokers 
with COPD compared to healthy smokers, but there is no difference between male and female 
smokers. Further, plasma levels of C-Reactive Protein, IL-6, and IL-8 did not have any 
significant sex differences. However, gene expression in circulating leukocytes, as measured by 
microarray, segregated clearly by sex using a principal component analysis. Immune system-
related genes were differentially expressed in males and females in response to smoke, among 
others.  
In clinical studies of human smokers and those with COPD, women experience smoking-
related disease risk and progression differently than men. For example, of patients in the 
COPDGene population, women with COPD have less emphysema than men when controlling 
for the degree of lung function [58, 59]. However, in sub-groups of COPD patients with severe 
or early-onset disease, women are more prevalent [59-61]. Additionally, women have equally 
severe emphysema despite less smoking history and experience a greater decline in lung function 
than men with similar smoking history [59, 62]. It has been previously observed that estrogen 
receptor expression is affected by cigarette smoking, which may partially explain the sex-
dependent phenotypes of smoke-induced chronic lung disease [63].  
The toxins present in cigarette smoke are passed to the bloodstream from the pulmonary 
alveoli, contributing to the systemic effects of cigarette smoke exposure. Gene expression 
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analysis of plasma and circulating lymphocytes has revealed many differences in expression 
between smokers and non-smokers [15, 64-68]. In at least one study, significant differences 
between male and female responses to cigarette smoke were found; the male-generated list of 
differentially expressed genes for smoking did not successfully separate female smokers from 
non-smokers, and vice versa [15]. The genes found to be differentially expressed by smoke in the 
peripheral lymphocytes were categorized into biological functions, including antioxidant stress 
response, immune response, cancer, and xenobiotic metabolism [15, 65].  
1.5. bENaC Mice as Models of (Human) COPD  
βENaC-transgenic mice were created by overexpressing the beta subunit of an epithelial 
sodium channel, encoded by the Scnn1β gene, under a Clara cell-specific promoter. The βENaC 
protein product is overexpressed in the lower airway epithelium, causing increased sodium 
absorption in the airways, which results in dehydrated mucus[69]. These mice present a 
phenotype that closely mimics human COPD because of the development of chronic bronchitis 
and emphysema in adult mice. This phenotype includes activated macrophages, increased mucin 
expression, and persistent increases in neutrophils and cytokines[70]. This is an improvement 
over the WT (C57Bl/6) smoke exposure mouse model and other current COPD mouse models in 
the field, which develop mild to moderate emphysema but do not develop chronic bronchitis at 
any stage or exposure level [8, 47].  
Previously in our lab, we have characterized the pathological pulmonary phenotype of the 
bENaC mice at baseline and after chronic smoke exposure. At baseline, the bENaC mice exhibit 
mucus hyperconcentration, mucus cell metaplasia, and obstruction of airways by mucus 
plugging, which mimics the chronic bronchitis pathology seen in human smokers with 
COPD[70, 71]. In addition, the mice experience mild-moderate emphysema at baseline and 
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develop changes in the immune cell populations in the lung, as shown by neutrophilic 
inflammation and foamy macrophages[70, 71]. Together, this phenotype mimics the changes 
seen in human COPD lung pathology. Although these mice exhibit COPD pathology at baseline, 
they are missing the cigarette smoke component to the disease, which has been shown to activate 
immune responses and change the lung microenvironment, such as by the induction of oxidative 
stress[25, 72].  Therefore, we combined the pathology caused by the genetic component with the 
environmental component of cigarette smoke with chronic (6 month) smoke exposure using a 
whole-body exposure system (Scireq). Our study design included WT sham, WT smoke, bENaC 
sham, and bENaC smoke exposure group to test the relative contribution of the cigarette smoke 
and lung pathology to COPD progression and to investigate the mechanisms by which this 
occurs.   
WT mice exposed chronically to cigarette smoke developed mild emphysema, while 
bENaC sham- and bENaC smoke-exposed mice developed significantly more severe 
emphysema than either treatment in WT mice[73]. bENaC mice also had increased numbers of 
macrophages in the airways compared to WT sham mice; this result shows that the bENaC 
genotype had more impact on the COPD phenotype than cigarette smoke exposure alone on 
immune cell infiltration. When gene expression in the whole lung tissue was profiled, cigarette 
smoke induced the expression of genes involved in oxidative stress and toxic stress 
responses[73]. These responses were not induced by the bENaC genotype alone, confirming the 
hypothesis that cigarette smoke contributes a unique aspect of COPD pathogenesis. The 
upregulation of oxidative stress and toxic stress responses occurred in both the WT and bENaC 
genotypes after smoke exposure, showing that this response is due to cigarette smoke 
independently. Gene set enrichment analysis (GSEA) showed that at the pathway level, NRF2-
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regulated genes and immune regulatory genes were upregulated significantly by smoke in the 
bENaC genotype but not in the WT genotype[73]. In addition, cigarette smoke exposure in 
bENaC mice induced significant immune suppression pathways, which was not seen in WT 
mice. This indicates that although certain individual genes respond similarly after cigarette 
smoke exposure in the  bENaC and WT genotypes, the pathways activated are distinct.  GSEA 
analysis was used to compare pathways upregulated in bENaC smoke-exposed mice to human 
COPD smokers, and significant enrichment of gene sets was found. Many of the pathways 
significantly enriched in the bENaC genotype compared to the WT genotype were similarly 
enriched in human COPD[73]. This indicates that our model has translational potential for the 




Chapter 2: Dynamic Changes in Murine Lung Gene Expression After Single and Repeated 
Exposures to Cigarette Smoke 
2.1. Overview 
Cigarette smoke is well recognized to cause injury to the airways and the alveolar walls 
over time. This injury usually requires many years of exposure, suggesting that the lungs may 
rapidly develop responses that initially protect it from this repetitive injury. Our studies tested 
the hypotheses that smoke induces changes in mRNA profiles that are dependent on sex and the 
health status of the lung, and that the effects of smoke are different after 1 day compared to 5 
days of exposure. Male and female wild type (WT) and Scnn1b-transgenic (bENaC) mice, which 
have chronic bronchitis and emphysematous changes due to dehydrated mucus, were exposed to 
cigarette smoke or sham air conditions for 1 or 5 days. Gene expression from lung tissue was 
analyzed. Overall, the response to cigarette smoke is similar at 1 compared to 5 days. Many 
genes and gene sets responded similarly: genes involved in oxidative stress responses were 
consistently upregulated while genes involved in the immune response were consistently 
downregulated. However, certain genes and biological processes were regulated differently after 
1 compared to 5 days. Extracellular matrix biology genes and gene sets were upregulated after 1 
day but downregulated by 5 days of smoke compared to sham exposure. By contrast, there was  
 
 
1This chapter is currently under review and will appear as an article published in PLoS One. It is reprinted 
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expression after single and repeated exposures to cigarette smoke. PLoS One.  
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no difference in the response to smoke between WT and βENaC mice and between male and 
female mice at either 1 or 5 days, suggesting sex and genotype affect gene expression 
independently from smoke. Taken together, these studies suggest that the lungs rapidly alter gene 
expression after only one exposure to cigarette smoke, with few additional changes after four 
more days of repeated exposure. These changes may contribute to preventing lung damage. 
2.2. Introduction 
Cigarette smoke is a leading health hazard and causes an enormous impact on lung 
health. Cigarette smoking has long been known to have a significant impact on respiratory health 
and diseases [1, 2]. Smoking is the number one cause of lung cancer and chronic obstructive 
pulmonary disease, and it increases the odds of developing either chronic bronchitis or 
emphysema [2, 3]. More than 16 million Americans are currently living with a tobacco smoke-
related disease, resulting in nearly $170 billion in direct healthcare costs annually [2, 4].    
The response of the lungs to the first exposure of cigarette smoke and how this response 
changes following subsequent exposures is important for understanding tobacco-induced lung 
injury and is nearly impossible to study in humans. Compared to a single stimulus, the lung’s 
response to repeated exposures of a stimulus such as endotoxin shows evidence of adaptation or 
tolerance [5], particularly when the stimulus induces oxidative stress in epithelial and immune 
cells [6]. The effect of a single exposure to cigarette smoke on gene expression in the lungs has 
not been evaluated. Most interesting are questions about changes that occur in response to a 
single dose of cigarette smoke compared to changes resulting from consecutive repeated 
exposures. The changes in gene expression, and particularly in pathways regulating host defense, 
can be used to evaluate how the lung adapts to cigarette smoke exposure. Additionally, many 
mouse models of smoking use acute exposure durations of fewer than 5 consecutive days of 
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cigarette smoke exposure [7, 8]. Understanding how the lungs cope with the oxidant burden and 
the many gaseous and particulate components of cigarette smoke initially and upon repeated 
exposures is likely to provide information about pathways and processes underlying host defense 
and the development of chronic lung disease.  
Males and females differ in their response to smoke exposure and the development of 
tobacco smoke-associated disease, such as chronic obstructive pulmonary disease (COPD) [2, 3]. 
COPD-associated morbidity and mortality are increased among American women compared to 
men [74, 75]. In fact, the highest prevalence of women with COPD occurs in North America 
[76]. Women and men with the same COPD burden respond differently; women experience more 
pronounced symptoms and report poorer quality of like than their male counterparts [77, 78]. 
This is true across the life course, and is particularly pronounced in younger women [79]. 
Additionally, women are more likely to develop severe, early onset COPD [58, 61]. Although the 
rise in the number of female smokers may contribute to the surge in female COPD prevalence, 
the difference in lung development and thoracic volume between the sexes may have a role [61], 
and importantly, the airway response to smoke is different between males and females [80]. 
Recently, certain sex-specific genetic risk factors for COPD have been identified for women [11, 
59]. Importantly, women are more likely to experience more severe dyspnea than men, despite 
similar lung function and with fewer pack-years of smoking history [81, 82]. Although this sex 
difference has been shown in humans who are chronic smokers, no studies investigate sex 
differences at early time points after initiation of smoking in humans. Additionally, to the best of 
our knowledge, no publication has assessed the effects of sex on the response of the lungs to 
acute smoke exposure in a mouse model to date. Given the differences in smoking-related lung 
disease incidence and pathology in humans, this is an important research question to pursue [9-
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15]. Understanding how sex impacts the development and initiation of tobacco smoke-related 
disease is important for developing treatment protocols for patients.  
The first exposure of cigarette smoke in humans will not always be to healthy lungs but 
rather to already inflamed lungs. Airway inflammation is common and has many etiologies. 
Viruses, other pathogens, environmental factors, and e-cigarettes or other “gateway” tobacco 
products can each cause airway inflammation. Understanding the impact of airway inflammation 
on the molecular changes in response to cigarette smoke is critical for our understanding of the 
effects of smoke in damaged lungs [39, 40]. Our approach to asking questions about the effect of 
smoke in lungs with inflammation uses a novel mouse model. Transgenic mice overexpressing 
Scnn1b, the gene that codes for the epithelial Na+ channel β subunit (bENaC), in the epithelial 
cells of the airways have dehydrated airway mucus that results in chronic bronchitis, including 
mucus cell metaplasia, mucus hypersecretion, mild neutrophilic inflammation, large foamy 
macrophages, and increased numbers of lymphocytes in both the lumen and the walls of the 
airways [69-71, 83-85]. Exposure of neonatal βENaC mice to cigarette smoke enhanced airway 
neutrophilia and mucus production and plugging [86]. In addition to chronic bronchitis, βENaC 
mice develop an emphysematous phenotype soon after birth. Their distal airspaces become 
enlarged secondary to obstruction from the pathologically thickened mucus [69]. This 
development of emphysema in βENaC mice requires upregulation of the metalloproteinase, 
MMP12, which can degrade alveolar walls [87]. The effects of 1- and 5-day cigarette smoke 
exposure in the healthy lungs of wild type (WT) mice and the chronically inflamed lungs of 
βENaC mice were therefore compared.  
These studies tested the hypotheses that smoke induces changes in mRNA profiles that 
are dependent on sex and the health status of the lung, and that the effects of smoke are different 
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after 1 day compared to 5 days of exposure. The changes over time during increasing acute 
exposure durations are likely to provide insight into the mechanisms important in protection 
against smoke-induced lung damage. 
2.3. Methods 
Mice: Male and female C57BL/6J wild type (WT) mice and Scnn1b-tg littermates 
(βENaC mice) [69] were bred and maintained in microisolator cages within ventilated racks in a 
pathogen-free facility with a 12-hour light/dark cycle and regulated temperature and humidity. 
Chow and water were provided ad libitum. Offspring were genotyped, and WT and βENaC mice 
were identified. All animal studies were performed in compliance with the U.S. Department of 
Health and Human Services Guide for the Care and Use of Laboratory Animals. All studies were 
approved by the UNC Chapel Hill Institutional Animal Care and Use Committee.  
Smoke exposure system and protocol: Sex-matched 5-7-week old WT and βENaC 
littermates were exposed to cigarette smoke or sham (room air) exposure.  Each exposure and 
genotype group included both males and females (n=5 animals of each sex per group for all 
groups except n=6 WT sham 5-day female mice, n=4 βENaC sham 5-day female mice, and n=4 
WT smoke 5-day mice). Exposure occurred in a plexiglass chamber attached to a smoke delivery 
device using an exposure chamber and smoking machine (inExpose Exposure System, SCIREQ, 
Chandler, AZ). The chamber contained pie-slice separators and positions for 16 mice. Mice were 
exposed to mainstream + side-stream smoke from 6 reference cigarettes with filters removed per 
day (College of Agriculture Reference Cigarette Program, University of Kentucky, 3R4F 
research cigarettes) [88].  Each cigarette was puffed using the standard Federal Trade 
Commission smoking machine protocol [88]. The mice received the equivalent of one puff per 
minute. The sham-exposed control mice were exposed to room air in the exposure chamber for a 
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time equivalent to that needed for active smoke exposure. Mice were exposed to cigarette or 
sham smoke for 1 day or 5 consecutive days. Samples were harvested 4 hours after the 
completion of the final smoke exposure. The right lung was used for gene expression analysis.  
Cotinine concentration in the plasma: Blood was collected from the inferior vena cava 
using EDTA as the anti-coagulant and centrifuged.  Plasma was frozen and stored.  Cotinine, a 
metabolite of nicotine, was measured using an ELISA (Mouse/rat Cotinine ELISA, Calbiotech, 
Spring Valley, CA, USA), following the manufacturer’s instructions.  
RNA isolation and gene expression analysis: RNA was isolated from lung tissue 
homogenates using the miRNeasy kit (Qiagen). Spectrophotometric ratios of A260/A280 and 
A260/A230 were 1.7-2.1 and greater than 1.6, respectively. RNA integrity number (RIN) values 
were greater than 7.4; the average RIN for all samples was 9.1. Affymetrix moGene2.1 array was 
used for gene expression analysis. Data were evaluated using Affymetrix Expression Console 
v1.4 software for quality control based on summary statistics, and Partek Genomics Suite v6.6 
for normalization. The manufacturer’s quality control thresholds were used 
(https://tools.thermofisher.com/content/sfs/brochures/exon_gene_arrays_qa_whitepaper.pdf). All 
samples passed all quality control metrics. One sample was identified as mislabeled based on 
cotinine concentration in the plasma and gene expression and was removed before proceeding 
for further analysis. Expression signals from CEL files were preprocessed and normalized 
by RMA (Robust Multiarray Average) background correction, GC content and probe sequence 
correction, quantile normalization, and median polish summarization of probe signals mapped to 
specific genes. Custom probeset-to-gene mappings were generated from Affymetrix Probeset 
and Transcript Annotation release 35 by consolidating all probesets mapped, in order of 
preference, to Ensembl 81 gene ID, Refseq mRNA, and Genbank accession numbers. The RMA-
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normalized log2 intensity values were used as input for analysis with the General Linear Model 
(glm) function in R. 
General Linear Model: The relationship between the gene expression and the variables of 
interest in the experiment (exposure, genotype, and sex) was modeled using a linear model. The 
linear model parses out the amount of expression change that is associated with each independent 
variable, and produces a b coefficient and a p value for each gene and each variable. Each gene 
may be influenced by one or more of these independent variables at one time – for example, a 
gene can respond to smoke exposure and also be expressed at different levels in males and 
females. Thus, a multivariable additive linear model containing the independent variables of 
smoke vs sham exposures (“exposure”), WT vs βENaC (“genotype”), and male vs female 
(“sex”) was fit to the gene expression data as the response variable This was performed 
separately for each exposure duration. The glm method in R was used to fit the expression of 
each gene (modeled as a normal distribution) and estimate the effect size (β coefficient) of each 
factor. The b coefficient represents the amount of expression change due to that variable alone. 
The p values corresponding to the β coefficients, which represent the significance of that effect, 
were transformed to q values using the Benjamini-Hochberg false discovery method[89] and a 
false discovery rate (FDR) of 5% was applied to identify significant effects. Genes below the 
threshold of q<0.05 and with a β coefficient larger than +/-0.379 (fold change >+/-1.3) were 
designated as “significant”.  
Identification of exposure-response genes: Lists of all genes with a significant (q<0.05) 
effect of exposure and a β coefficient larger than +/-0.379 (fold change >+/-1.3) were compiled 
separately for 1-day and 5-day exposures. These are referred to as “exposure-response genes”. 
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Genes with a positive β coefficient are upregulated in the smoke-exposed mice, while genes with 
a negative β coefficient are downregulated in the smoke-exposed mice.  
Overlap analysis: Overlap analysis was used to test for enrichment of GSEA Canonical 
Pathways processes in gene lists. Custom gene lists derived from each cluster in the heatmap as 
well as the list of exposure duration-dependent genes were tested for significant overlap with the 
Canonical Pathways gene sets’ gene lists using the MSigDB overlap computation tool 
(http://software.broadinstitute.org/gsea/msigdb/help_annotations.jsp#overlap). The hyper-
geometric distribution was used to produce statistical estimates of the significance of the overlap.  
A custom gene list of the genes different between WT and bENaC, derived from the 
published results in Saini et al [71], was tested for overlap with the 1-day and 5-day genotype-
response gene lists derived from our analysis. Separately, a custom gene list of the genes 
different between WT mice exposed to either smoke or sham conditions for six months, derived 
from the published results in Miller et al [90], was tested for overlap with the 1-day and 5-day 
exposure-response gene lists derived from our analysis. The testGeneOverlap function from the 
GSA and GeneOverlap libraries, which performs a Fisher’s exact test based on the gene lists 
input, was used to calculate significance of the overlap.  
Clustering and heatmap generation: K-means clustering was used to group the genes into 
clusters with distinct expression patterns which were linked to biological functions through 
evaluation of gene annotations. Hierarchical clustering, using Pearson correlation, was used to 
group the samples in order to understand the similarities among samples. To determine the 
number of gene clusters that best describes the dataset, the within-group sum of squares for 2 to 
20 clusters was plotted (i.e. the elbow method), and k=5 clusters was chosen to capture the major 
patterns. Five clusters showing the expression of all exposure-response genes across samples 
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were generated using the k-means clustering function from R (k=5, with the best of 50 random 
starts). A heatmap of 5 k-means gene clusters was generated using the Bioconductor R package, 
ComplexHeatmap [91], with hierarchical clustering (for each k-means cluster) with Euclidean 
distance metric was used for the genes, and Pearson correlation was used for the samples.  
Analysis of genes within clusters: The pooled list of exposure-response genes significant 
at 1 and/or 5 days (556 genes) were used for the heatmap. Each of the gene lists for the k-means 
clusters were input separately into GSEA’s overlap calculation tool and Ingenuity Pathway 
Analysis (IPA) to determine enrichment and association with biological pathways and to identify 
predicted upstream regulators. The results from both GSEA and IPA canonical pathway 
enrichment tests were assimilated and summarized.  
Identification of exposure duration-dependent genes: To test for interaction of exposure 
(smoke versus sham) and exposure duration (1 versus 5 days), gene expression was modelled in 
a post-hoc test using exposure, exposure duration, and an interaction term between these 
variables for all significant exposure-response genes. Genes that had a significant interaction 
term (q<0.05), i.e., responded differently at 1 and 5 days, were reported as “exposure duration-
dependent genes”.  
Comparison of gene expression responses between 1-day and 5-day exposures: 
Responses of gene expression to smoke exposure, genotype, or sex, as shown by β coefficients 
for 1 day and 5 days, were plotted and compared using the correlation test (cor.test) in R. 
Regression lines and confidence intervals were plotted using the R package, DescTools.  
Gene set analysis: Gene set analysis was adapted from the Gene Set Enrichment Analysis 
(GSEA) [92] method, using the signed -log(p value) as the test statistic [92, 93]; all genes, 
regardless of significance of the q values, were included in this analysis. The p value evaluates 
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the strength of association with exposure and how well we can detect it, while the sign of the b 
coefficient was included to reflect the direction of change in response to the variable of interest. 
Briefly, the sum of test statistics for each gene in the gene set was divided by the square root of 
the number of genes in the gene set, creating an average score for the entire gene set, to produce 
the composite “GSA score” for the gene set. The Canonical Pathways list (GSEA, Broad 
Institute, version 5.2) was used; the input genes were filtered to include only those with identical 
symbols between mouse and human in a case-insensitive manner. The threshold for gene set 
significance was estimated empirically from 1000 random permutations of sample labels [94]. 
Significant gene sets were identified with a 5% FDR threshold [89]. The summary table of the 
results of permutation testing are included in Figures 2.7 and 2.8.  
Selected gene set analysis (extracellular matrix biology gene sets from the literature): 
Customized gene lists derived from Burgstaller et al. [95] was used to evaluate the association of 
exposure and extracellular matrix components. Sample-based permutation testing (n=1000 
permutations) was done to estimate the background level of association with the gene sets.  
Ingenuity Pathway Analysis: In order to get a more complete picture of the biological 
processes represented in the exposure-response genes identified, a second database of gene sets 
was used. IPA’s gene sets, which were derived from several databases and compiled from 
published literature, are distinct from GSEA’s Canonical Pathways list, which is derived from 
several databases compiling published literature. The networks and functional analyses were 
generated through the use of Ingenuity Pathways Analysis (version 2.3, 
https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis/)[96]. 
Accession code: The microarray data have been deposited into the Gene Expression 




Cotinine concentration in the plasma. Plasma samples were obtained 4 hours after the 
conclusion of the 1- or 5-day exposures from the same mice in which gene profiling was 
performed, and the concentration of cotinine was measured. No cotinine was detected in any 
sample from sham-exposed mice (Table 1). Cotinine was present after 1- or 5-day exposures to 
cigarette smoke, and there was no difference in 1-day compared to 5-day exposures when each 
sex and genotype are compared individually. When values from males and females of both 
genotypes are pooled, 1-day exposures resulted in a higher plasma cotinine concentration than 5-
day exposures (52.1 + 4.9 ng/mL after 1-day exposure vs. 33.4 + 5.4 ng/mL after exposure for 5 
days, p = 0.001).  
Exposure, genotype, and sex cause changes in hundreds of genes in the gene expression 
profile. In order to explore the variation within each duration of exposure and compare the 
responses, the samples from the 1-day and 5-day exposure durations were analyzed separately. 
To assess gene expression changes at 1 compared to 5 days of smoke exposure, the number of 
significant genes associated with exposure (smoke vs sham), genotype (WT vs βENaC), and sex 
were recorded (Table 2).  
 This analysis showed that after 1 and 5 days of smoke, exposure caused hundreds of 
genes to change significantly (330 and 347 genes, respectively, Appendices 3 and 4). Genotype 
has the greatest impact on the gene expression profile, showing the largest number of impacted 
genes after both 1 and 5 days (467 and 772 genes, respectively). The number of sex-response 
genes varies greatly, from 253 genes changed after 1 day of smoke to 59 genes changed after 5 
days of smoke.  
The exposure-response gene profile clusters into five distinct clusters, which represent 
different biological pathways. To visualize the patterns of gene expression changes associated 
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with exposure, the normalized log2 intensities of the combined 556 exposure-response genes 
from 1 and 5 days (hereafter, the “pooled exposure-response genes”) were compiled and 
clustered using k-means and hierarchical clustering (Fig 1). The samples segregated first into 
smoke and sham, as expected, with two distinct groups of sham-exposed samples. Among the 
smoke-exposed samples, there was further grouping by exposure duration (1 day vs 5 days), 
which was not present in the sham-exposed samples. Among the sham-exposed samples, there 
was further grouping by genotype (WT vs βENaC). Genotype did not segregate within the 
smoke-exposed groups, and there was no segregation by sex in any group.  
The 556 exposure-response genes clustered into five clusters with distinct expression 
patterns using the k-means algorithm. Three clusters (2, 3 and 4) contain genes that were 
downregulated in response to smoke, and two clusters (1 and 5) contain genes that were 
upregulated in response to smoke. The list of the genes in each cluster was then input into both 
GSEA and Ingenuity Pathway Analysis to understand the biological pathways represented. A 
summary of the Canonical Pathways that are significantly enriched in each cluster and how these 
genes respond to smoke exposure is presented in Table 3.  
Clusters 1 and 5 contain genes upregulated in response to smoke. Genes in Cluster 5 are 
associated with cytoprotective processes to oxidative stress, including NRF2-mediated responses 
to oxidative stress and glutathione-mediated detoxification. The xenobiotic response, as mediated 
through cytochrome P450 enzymes, is also associated with this gene list. The genes in Cluster 1 
are associated with processes such as nicotine degradation, drug metabolism by cytochrome 
P450 enzymes, glutathione-mediated detoxification, and estrogen biosynthesis.  
Genes within Clusters 2 and 4 are downregulated in response to smoke. Cluster 2 genes 
are associated with the regulation and organization of the extracellular matrix (ECM). Pathways 
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such as those involved in the matrisome, collagen formation, and ECM organization are 
enriched. A subset of the Cluster 2 genes are upregulated after 1 day of smoke exposure but 
downregulated by 5 days. Interestingly, Cluster 4 genes also appear to have different responses 
to exposure duration in the smoke-exposed animals: they are downregulated to different 
magnitudes after 1 compared to 5 days of smoke. However, Cluster 4 genes are not significantly 
associated with any canonical pathways. 
The downregulated Cluster 3 genes are enriched for biological pathways encompassing 
many aspects of the immune system response, such as granulocyte, monocyte, and B lymphocyte 
pathways. Immune responses including the Fc gamma receptor-mediated phagocytosis in 
macrophages and monocytes, phagosome formation, and the role of pattern recognition receptors 
in recognition of bacteria and viruses are also associated with the gene list from Cluster 3.  
A minority of exposure-response genes are also influenced by genotype and/or sex 
independently. In order to understand the changes due to smoke in these exposure-response 
genes, it is important to understand whether the baseline expression level in sham-exposed mice 
is different between sexes and/or genotypes. We hypothesized that there are genotype- and sex-
specific effects occurring during smoke exposure. Overall, there is no difference resulting from 
smoke exposure in males compared to females or in bENaC mice compared to WT mice. Our 
analysis showed no dependent relationship between smoke exposure and either genotype or sex. 
However, many independent effects were identified (Fig 2A), suggesting the effects of exposure, 
genotype, and sex on gene expression are largely additive. Many of the exposure-response genes 
are also influenced by genotype and/or sex; the changes in gene expression from all variables 
together make up the total change in the gene’s expression compared to wild type sham-exposed 
mice. For 56% of the exposure-response genes at 1 day and 41% of the exposure-response genes 
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at 5 days, the gene expression is changed significantly by both exposure and at least one other 
variable, independently. For example, 93 genes were associated with both exposure and sex after 
1 day of smoke exposure (Fig 2A). Therefore, while we did not find many significant dependent 
relationships between exposure and either genotype or sex, the expression of many exposure-
response genes is further influenced by genotype and sex, independently.  
Changes in the exposure response after 1 compared to 5 days of smoke. We next asked 
whether the exposure-response gene expression profiles at 1 and 5 days were different by 
assessing how many of the exposure-response genes were uniquely responsive at each exposure 
duration and how many were commonly significant after both 1 and 5 days of exposure. 
Although the number of changed genes is similar between 1 and 5 days, only 229 of these are 
changed after both 1 and 5 days. Of the 556 total genes that changed in response to exposure, the 
majority of the exposure-response genes (327 genes, 59%) have a specific, duration-dependent 
response (Fig 2B).  
Although there are specific genes that have a duration-dependent response, overall, the 
exposure response at 1 and 5 days is similar. To further compare the gene expression response to 
smoke exposure at these durations, we also looked at the correlation of b coefficients within the 
pooled response genes (Fig 3). Genotype- and sex-response genes have greater correlations (0.94 
and 0.91, respectively) and slopes very close to one when comparing exposure durations, 
showing that the impact of smoke is approximately the same after a single exposure as after 
repeated exposures for 5 days (Fig 3). Exposure has the greatest variability of response between 
these exposure durations. The correlation coefficient of 0.77 and slope of 0.76 shows that the 
responses after 1 and 5 days of exposure are generally similar. However, some genes show 
different behavior that is exposure duration-dependent, as evidenced by a significant interaction 
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between exposure and exposure duration (red dots in Fig 3A). We hypothesized that these genes 
exhibiting exposure duration-dependent behavior reflected important differences in the lung’s 
response after the first compared to repeated exposures to cigarette smoke.  
Gene sets describing the function of duration-dependent exposure-response genes include 
ECM and oxidative stress pathways. In fact, 165 exposure-response genes had significantly 
different responses at each exposure duration (Appendix 5; red dots, Fig 3A). An overlap 
analysis was performed using this gene list and the GSEA’s Canonical Pathways list to 
determine if these genes represented any functional pathways that respond differently between 1 
and 5 days of exposure (Table 4). Several of the associated gene sets fell into two categories: 
oxidation/conjugation of glutathione and regulation of the extracellular matrix (ECM). The 
duration-dependent exposure-response gene list had the most significant overlap with the NABA 
Matrisome gene set; 21 of the 165 duration-dependent exposure-response genes (q=4.15e-10). 
The second most highly enriched gene set was the Reactome Biological Oxidations list, with 8 
genes overlapping (q=2.04e-6). These results suggest a role for processes regulating the 
oxidation/conjugation of glutathione and aspects of ECM biology, including the matrix structure 
and the attachments of cells to the matrix, in the modulation of the lung’s response to cigarette 
smoke.  
The top gene sets significantly associated with both 1- and 5-day exposure responses 
represent xenobiotic and antioxidant response pathways. We next asked whether pathways 
involved in similar biological processes were becoming further stimulated or repressed over 
increasing exposure duration. After 1 day of exposure, 261 gene sets were significantly 
associated with the exposure response (Appendix 1). After 5 days of exposure, 412 gene sets 
were significantly associated with the exposure response (Appendix 2).  
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Xenobiotic responses, often through cytochrome P450, and antioxidant responses, often 
through the pathways of glutathione metabolism, are the most highly associated and are 
increased after both 1 and 5 days of exposure (Appendices 1 and 2). These biological pathways 
have been identified in several previous studies as highly responsive to cigarette smoke [40, 97, 
98]. 
A subset of exposure-associated gene sets respond differently to smoke at 1 compared to 
5 days of exposure. Gene sets that are discordant by exposure duration change their direction of 
response to cigarette smoke between the first exposure and 5 days of exposure. The discordant 
exposure-associated gene sets provide some insight into how the lung modulates its response to 
cigarette smoke between the first exposure and 5 days of repeated exposures. The exposure-
associated gene sets that were downregulated at 1 day but upregulated due to smoke after 5 days 
(Table 5) include both oxidative phosphorylation and the TCA cycle/respiratory electron 
transport. Moreover, the gene sets that are first upregulated but become downregulated in 
response to smoke after 5 days primarily include processes regulating the ECM. We therefore 
hypothesize that differential regulation of oxidative phosphorylation and ECM biology are 
among the processes changed by the lungs that account for the differential exposure response 
between the 1-day and 5-day durations.  
Gene sets that responded similarly after both 1 day and 5 days of smoke exposure are also 
listed in Table 5. The gene sets that were downregulated after both 1 and 5 days of exposure are 
exclusively gene sets involved in immune processes. Among the gene sets that were upregulated 
in response to smoke after both 1 and 5 days, oxidative processes are the most numerous, 
although gene sets representing immune processes, changes in metabolism and energy sources, 
transcription factors, and hypoxia are also present. These results provide insight into the lung’s 
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response to smoke exposure which do not appear to be differentially modulated between these 
two acute exposure durations.  
A more comprehensive look at ECM gene sets associated with exposure shows 
upregulation after 1 day and downregulation after 5 days of smoke. ECM biology regulation was 
significantly associated with smoke in the gene set association analyses and is recognized as 
important in cigarette-induced lung injury. In a recent review [95], Burgstaller and colleagues 
have carefully characterized the proteins involved in the ECM of the lung through mass 
spectrometric methods and provided the genes encoding them [95]. Since this comprehensive list 
of genes has not yet been added to the GSEA database, we created custom gene set lists derived 
from this publication and tested them for association with exposure in our dataset. The gene sets 
derived from this composite list of all ECM proteins, as well as the subset containing only 
glycoproteins, were significantly associated with exposure at both 1 and 5 days. Furthermore, 
these gene sets behaved discordantly with exposure duration: both the composite list of ECM 
components and the glycoproteins subset were upregulated after 1 day but downregulated after 5 
days of smoke (Table 6). Interestingly, the data show that ECM gene expression was strongly 
associated with sex, and that expression of ECM genes was increased in male compared to 
female lung tissue.  The few differences seen when genotypes are compared are small and 
inconsistent.  
The impacts of genotype and sex on gene expression occur independently from exposure 
in acute exposure responses. The impacts of sex and genotype on the gene expression profile of 
the lungs are significant, as shown by the hundreds of genes and gene sets significantly 
associated with genotype and sex (Table 2). Furthermore, sex and genotype explain significant 
variation in expression (Table 2.9).  
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Additionally, the genotype-response genes significantly overlap with published gene 
DEGs [71] for the βENaC mice compared with WT for both the 1-day and 5-day genotype-
response gene lists (p=3.3e-71 and p=1.5e-74, respectively), confirming that the experimental 
and analytical methods are robust (Figure 2.5). Our genotype-response gene lists also include 
many additional genes showing a significant difference between βENaC and WT mice with a 
fold change of at least 1.3.  
Although large differences in the numbers of sex- and genotype-response genes were 
identified at 1 day compared to 5 days of exposure (Table 2), the b coefficients of these genes for 
1 day compared to 5 days have a significant correlation (Fig 3). Therefore, although individual 
genes may be responding in an exposure duration-dependent manner, there is no evidence for 
exposure duration-dependent sex or genotype differences in the gene expression profile at these 
acute exposure lengths. Taken together with the lack of dependent interactions with exposure at 
the individual gene level, genotype- and sex-associated changes thus appear to occur 
independently of smoke exposure and of exposure duration.  
A comparison of the acute exposure responses with a published study of chronic smoke 
exposure in mice. The exposure-response genes identified after 1 and 5 days of smoke represent 
the lung’s response to a single and five consecutive daily doses of smoke. In order to explore 
how these responses compared to gene expression in the lung in an established environment of 
chronic smoke exposure, we compared these gene lists to DEGs identified in WT mice after six 
months of smoke exposure [90]. Miller and colleagues identified 111 genes that were 
differentially expressed in smoke- compared to sham-exposed WT mice. There was significant 
overlap between this list of DEGs and our results. After 1 day, 26 of the exposure-response genes 
were also identified after 6 months of smoke exposure (p=2e-24). After 5 days of smoke 
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exposure, 40 of the exposure-response genes were also identified by Miller et al’s study (p=8.6e-
45).  
2.5. Discussion and Conclusions 
Understanding how the lungs cope with cigarette smoke, particularly the oxidant burden, 
initially and upon repeated exposures, provides information about pathways and processes 
underlying host defense and the development of chronic lung disease. The response of the lungs 
to the first exposure of cigarette smoke and how this response changes following subsequent 
exposures cannot be ethically studied in humans, underlining the critical value of murine studies. 
Our study tested the hypothesis that the pulmonary response to cigarette smoke, as measured by 
expression of exposure-response genes and the association scores of gene sets, is different 
between 1 and 5 days of cigarette smoke. The most novel and exciting information comes from 
the opportunity to study two acute durations of smoke and to determine whether the lung’s 
response changes over this short interval. We determined the changes in gene expression in order 
to evaluate in an unbiased manner how the lung adapts to acute cigarette smoke exposure. These 
changes in expression were then analyzed to identify the processes and mechanisms through 
which adaptation may be occurring, through gene set analysis.  
Our study design compared mice exposed to cigarette smoke for a single session to mice 
exposed to five times that cumulative dose delivered over five consecutive days. Our study 
shows that after both 1 and 5 days of smoke exposure, the lung responds with the up- and 
downregulation of hundreds of genes. Interestingly, certain gene networks are upregulated after 
the first exposure to cigarette smoke but become downregulated by 5 days of exposure, such as 
processes regulating the ECM. In contrast, processes regulating the immune response are 
consistently downregulated after both 1 and 5 days of smoke. Furthermore, other gene sets 
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representing the biological pathways of oxidative stress and xenobiotic responses are 
consistently upregulated in response to smoke. For example, at both 1 and 5 days there is a 
significant upregulation of NRF2-mediated cytoprotection to the oxidative stress response and of 
gene sets describing glutathione-mediated detoxification. Therefore, the gene expression profile 
and, specifically, the exposure response, is similar after 1 and 5 days of exposure, but contains 
important differences in gene expression representing biological functions that show the lung 
modulates its response to smoke.  
To address concerns about replicability, we compared the lists of genotype-response 
genes at 1 and 5 days to previously reported genotype-response genes in βENaC and WT mice of 
the same age [71]. There was significant overlap between the published gene list and the 1 day 
(75% overlap) and 5 day (85% overlap) genotype-response gene lists (Figure 2.5). Therefore, the 
genotype results successfully replicate previous findings, validating both the biological results 
and the technical methods used to discover the response genes in this study. Additionally, these 
data support our observation that the genotype changes occur independently from the smoke 
exposure responses at these acute durations.  
Certain biological functions respond to the presence of cigarette smoke no matter how 
many times the lung has been exposed to smoke. In fact, most genes respond similarly between 1 
and 5 days of exposure, as shown by the correlation coefficient of 0.77 in Fig 3A. Specifically, 
the xenobiotic and antioxidant responses are the most highly associated with exposure and are 
increased after both 1 and 5 days. These responses have previously been reported in the literature 
at chronic smoke durations for humans [99] and mice [40, 100], and observed even at sub-
chronic (4 and 8 week) exposure durations in mice [101]. The gene sets that are upregulated in 
response to smoke after both 1 and 5 days involve diverse processes from oxidative stress and 
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metabolic functions. These results provide insight into aspects of the lung’s response to smoke 
exposure that is likely independent of exposure duration. For example, the NRF2-mediated 
cytoprotective response to oxidative stress pathway is upregulated after 1 and 5 days of exposure 
(Fig 4A). Mice deficient in the gene that codes for Nrf2 (Nfe2l2) show accelerated and enhanced 
injury induced by cigarette smoke [102, 103]. After 1 day of smoke exposure, pathways 
involving cytoprotection of cells via Nrf2 are predicted to be changed (Fig 4B). By 5 days of 
exposure, the oxidative stress response pathways regulating glutathione conjugation via Nrf2 
regulation are predicted (Fig 4C). Our data provide insight into which Nrf2-regulated genes may 
be mediating this protection. Alterations in antioxidant responses together with metabolic 
changes in the lung are well documented in response to cigarette smoke and have been 
implicated in the development of COPD [104]. Therefore, these responses are present and 
measurable after a single exposure to cigarette smoke and are maintained through consecutive 
repeated exposures, and they remain at chronic time points. Thus, Nrf2 is an important aspect of 
the mechanism through which smoke exposure regulates gene expression changes [102, 103].  
Strikingly, the gene sets that were downregulated after both 1 and 5 days of exposure are 
involved in virtually every aspect of immunity. Changes in the immune system of the lung in 
response to chronic cigarette smoke exposure have previously been documented in humans 
[104], and have been found to be conserved in comparisons between human and mouse 
responses to chronic smoke[40]. Decreases in the numbers of inflammatory cells and 
chemokines and immune suppression have also been well-documented as responses to smoke 
exposures [105-108].  
The most interesting questions address differences that occur in response to a single dose 
of cigarette smoke to those resulting from consecutive repeated exposures. Exposure duration-
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dependent gene responses are denoted by a significant interaction between exposure and 
exposure duration. These genes are enriched in gene sets regulating biological processes such as 
the oxidative stress response through glutathione oxidation, metabolism pathways, xenobiotic 
responses, and the ECM biology (Table 4). ECM biology has long been associated with chronic 
smoke exposure [88, 95, 97, 109, 110]. However, a comparison of the response after acute 
smoke, and particularly after a single compared to five consecutive doses of cigarette smoke has 
not been previously assessed, to the best of our knowledge. Importantly, there are no genotype- 
or sex-associated pathways which act discordantly by exposure duration, suggesting that these 
changes are independent of exposure duration. We suggest that the different changes in response 
to exposure duration may represent the lungs’ attempt to adapt to repeated exposures, which 
ultimately results in the matrix changes and the effects of abnormal immune responses that is 
eventually manifested as chronic obstructive pulmonary disease. 
Pathways and genes modulating the ECM showed a discordant response to exposure 
duration; although these pathways are initially upregulated in response to smoke after 1 day of 
exposure, they are downregulated by 5 days. This suggests that smoke rapidly induces genes, 
including structural genes coding for collagens and laminins, in response to acute cellular injury. 
By 5 days of smoke exposure, the cytoprotective effects of Nrf2 target activation and other 
antioxidant processes may result in less need for these ECM repair mechanisms at this point in 
the lung’s response.  
ECM biology-related gene sets derived from Burgstaller and colleagues’ recent review of 
ECM biology [95] in the lung replicated the association with smoke and discordant behavior due 
to exposure duration: the ECM gene set containing all ECM components was significantly 
upregulated due to smoke after 1 day, but downregulated after 5 days (Table 6). ECM 
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remodeling in response to chronic cigarette smoke has been recorded before in animal models 
[56, 109, 111]. Subsets of the ECM gene sets deal with different facets of ECM biology, 
including ECM components and their regulation and cell-matrix interactions, and provide 
information about the way the lung reshapes the ECM in response to cigarette smoke. The gene 
set composed of glycoprotein-encoding genes from the recent ECM review showed significant 
association with smoke and behaved discordantly with exposure duration: this gene set was 
significantly upregulated due to smoke after 1 day but downregulated after 5 days (Table 6). 
Furthermore, this association with smoke and the discordant changes by exposure duration was 
present in the glycoprotein subset only and not in the collagen or proteoglycan subsets, although 
the composite list of all components did respond similarly (Table 6). Additionally, there is 
evidence of an effect of estrogen in ECM remodeling in mice exposed to chronic cigarette smoke 
[110]. This corresponds with the enrichment of estrogen biosynthesis genes within the exposure-
response gene list (Table 3).  
The pathways identified as changed in our study after 1 and 5 days of cigarette smoke are 
concordant with those listed in the literature as being changed after chronic smoke exposures of 
at least six months, at both the mRNA and protein levels. In one recent study, a proteome 
analysis shows similarly differentially regulated pathways after chronic smoke exposure, 
including xenobiotic metabolism, oxidative stress, and cytochrome P450 enzymes and responses 
[112]. The authors also identified mitochondrial dysregulation after 12 months of smoke 
exposure [112]; this relates to the list of gene sets seen to be upregulated after 1 day and 
downregulated by 5 days of smoke exposure (Table 5). Studies looking at gene expression after 
chronic smoke exposure also show differential expression in the xenobiotic metabolism, 
oxidative stress, and cytochrome P450 enzymes and response pathways in both humans and mice 
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[40, 97, 98]. Additionally, a recent analysis of the secreted proteins from ex vivo mouse lung 
cells exposed to cigarette smoke showed that proteins involved in extracellular matrix 
organization were downregulated [113]. These studies therefore suggest that the early adaptation 
of the lung to cigarette smoke leads to the permanent changes established after chronic smoking.  
This study looked at RNA from the total homogenized lung tissue, which is a very 
heterogeneous mixture of numerous cell types. These methods are ideal for discovery of smoke-
response genes in the transcriptome that are highly expressed after acute smoke exposures and 
for generation of new hypotheses. However, this also creates the limitation that the methods did 
not allow for identification of the cell population of origin for each differentially expressed gene. 
Future studies could identify the source of these changes and the signaling pathways responsible 
for the functional changes.  
We hypothesized that there would be genotype- and sex-specific responses to acute 
smoke exposures. However, an interaction test to identify genes that responded differently to 
smoke depending on genotype or sex showed that these dependent relationships were not present 
in the dataset (Table 2.9). This result could be a true negative result, or it could be that the 
sample size was too small to detect these interactions. While we did not find many significant 
dependent relationships between exposure and either genotype or sex, the expression of many 
exposure-response genes is further modulated by genotype and sex, independently. Additionally, 
these changes correlate almost perfectly between 1 and 5 days of smoke exposure (Fig 3), 
showing that there are no overall exposure length-dependent changes in the genotype- or sex-
response genes. Taken together, the genotype- and sex-associated changes occur independently 
of smoke exposure and of exposure duration. Although individual genes may be responding in an 
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exposure length-dependent manner, there is no evidence for exposure length-dependent sex or 
genotype differences in the gene profile changes at these acute exposure lengths.  
Gene expression analysis comparing the lung’s response to the first and repeated 
consecutive cigarette smoke exposures provides information and generates hypotheses to help 
direct future research questions. Understanding the ways in which the lungs modulate their 
response to cigarette smoke after repeated exposures can contribute new information about the 
toxicology of smoke and eventually contribute to understanding the therapeutic potential in 




Table 2.1.  Concentration of cotinine in plasma (ng/mL plasma).  Cotinine concentration in 
the plasma samples show a clear distinction between smoke- and sham-exposed animals and are 
not significantly different with regards to sex or genotype. Data are expressed as mean + SEM. N 
= 5 per group except n=6 WT sham 5-day female mice, n=4 βENaC sham 5-day female mice, 
and n=4 WT smoke 5-day male mice).   
 
 1-day exposure 5-day exposure 
Genotype Sham Smoke Sham Smoke 
WT mice     
      Male None detected 44.8 + 5.3 None detected 35.6 + 9.2 
      Female None detected 47.6 + 3.8 None detected 31.0 + 7.7 
βENaC mice     
      Male None detected 52.1 + 10.9 None detected 40.3 + 3.7 





Table 2.2.  Differences in the number of genes influenced by each variable of interest. 
Smoke exposure, genotype, sex, and exposure duration all contribute important information to 
the gene expression profile. Only genes with a significant association (q<0.05) with the variable 
of interest and a fold change >+/-1.3 are recorded. 
 
 
  1 day 5 days 
Exposure 330 347 
Genotype 467 772 




Table 2.3.  Changes due to exposure at 1 and/or 5 days. The clusters, depicted in Fig 1, are 
summarized. The key genes were identified as the top 3 genes up or downregulated by smoke; 
the top genes from 1 and 5 days were assimilated together into one list. Representative pathways 
were determined by significant enrichment in the Canonical Pathways from either the GSEA or 









Cluster Key genes 
1 






Ces1g 2.07 2.61 
Upregulated 
Drug Metabolism by 
Cytochrome P450 
Ptgs2 1.37 0.64 Biological Oxidations 
1810010H24Rik 0.82 0.50 Nicotine Degradation II 
Slc4a1 0.71 1.89 
Glutathione-mediated 
Detoxification 
Apol11b 0.43 1.56 Estrogen Biosynthesis 
2 
Pigr -0.59 -0.01 
Downregulated 
Matrisome 
Slurp1 -0.63 -0.28 ECM Glycoproteins 
Plcb1 -0.74 -0.92 Chemokine Signaling 
Ighv12-3 -0.20 -1.08 ECM Regulators 
Spon2 -0.46 -1.22 
Cytokine-Cytokine 
Receptor Interaction 
Clca3 1.15 -1.61 Collagen Formation 
Adamts17 0.61 -0.79 Focal Adhesion 
Eln 0.54 -0.39 ECM Organization 
3 
   
Downregulated 
Immune System  
Serpinb10 -1.05 -0.81 Granulocytes Pathway 
Emr4 -1.12 -1.05 Interferon Signaling 
Ifitm6 -1.14 -0.87 Phagosome Formation 
Ccr3 -0.68 -0.91 
Role of Pattern 
Recognition Receptors 
in Recognition of 
Bacteria and Viruses 




Slc10a5 -0.79 -0.08 
Downregulated 
  
Igkv4-80 -0.81 -1.02 
No canonical pathways 
with 
Ccdc129 -1.15 -0.22 significant association 
Aplnr -0.21 -0.74   
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Fabp1 -0.26 -1.13   
5 





Slc7a11 3.65 1.69 
Glutathione 
Biosynthesis 




Nqo1 2.87 2.64 
Xenobiotic Metabolism 
Signaling 







Table 2.4.  Gene sets enriched in the exposure-response genes with significantly different 
behavior at 1 compared to 5 days. An overlap analysis performed by GSEA comparing the list 
of genes with significantly different behavior at 1 compared to 5 days of smoke exposure, as 
defined by a significant interaction effect between exposure and exposure duration (red dots in 
Fig 3A) to the Canonical Pathways gene set list. These genes overlap most significantly with 
several oxidative response gene sets, as well as those regulating ECM biology. 
 









NABA_MATRISOME 1028 21 4.15E-10 
REACTOME_BIOLOGICAL_OXIDATIONS 139 8 2.40E-06 
NABA_CORE_MATRISOME 275 9 2.24E-05 
REACTOME_GLUTATHIONE_CONJUGATION 23 4 1.25E-04 
NABA_MATRISOME_ASSOCIATED 753 12 1.67E-04 
REACTOME_NCAM_SIGNALING_FOR_NEURITE_OUT
_GROWTH 64 5 1.67E-04 
NABA_ECM_GLYCOPROTEINS 196 7 1.73E-04 
REACTOME_AMINO_ACID_TRANSPORT_ACROSS_T
HE_PLASMA_MEMBRANE 31 4 2.19E-04 
REACTOME_NCAM1_INTERACTIONS 39 4 5.00E-04 
REACTOME_AXON_GUIDANCE 251 7 6.15E-04 
REACTOME_TRANSPORT_OF_INORGANIC_CATION
S_ANIONS_AND_AMINO_ACIDS_OLIGOPEPTIDES 94 5 6.15E-04 
REACTOME_AMINO_ACID_AND_OLIGOPEPTIDE_SL
C_TRANSPORTERS 49 4 9.47E-04 
KEGG_GLUTATHIONE_METABOLISM 50 4 9.48E-04 
REACTOME_DEVELOPMENTAL_BIOLOGY 396 8 9.75E-04 
REACTOME_TRANSMEMBRANE_TRANSPORT_OF_S
MALL_MOLECULES 413 8 1.23E-03 
REACTOME_SULFUR_AMINO_ACID_METABOLISM 24 3 2.62E-03 
REACTOME_PHASE1_FUNCTIONALIZATION_OF_CO
MPOUNDS 70 4 2.62E-03 
REACTOME_PHASE_II_CONJUGATION 70 4 2.62E-03 
REACTOME_SLC_MEDIATED_TRANSMEMBRANE_T
RANSPORT 241 6 3.03E-03 
KEGG_ECM_RECEPTOR_INTERACTION 84 4 4.82E-03 
REACTOME_METABOLISM_OF_AMINO_ACIDS_AND_
DERIVATIVES 200 5 1.17E-02 
KEGG_FOCAL_ADHESION 201 5 1.17E-02 
REACTOME_ETHANOL_OXIDATION 10 2 1.63E-02 
NABA_SECRETED_FACTORS 344 6 1.63E-02 
REACTOME_SIGNALING_BY_PDGF 122 4 1.63E-02 
NABA_ECM_REGULATORS 238 5 2.14E-02 
KEGG_ARACHIDONIC_ACID_METABOLISM 58 3 2.29E-02 
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REACTOME_COLLAGEN_FORMATION 58 3 2.29E-02 
KEGG_CIRCADIAN_RHYTHM_MAMMAL 13 2 2.37E-02 
REACTOME_METABOLISM_OF_PORPHYRINS 14 2 2.67E-02 
PID_INTEGRIN1_PATHWAY 66 3 3.02E-02 
REACTOME_GPCR_LIGAND_BINDING 408 6 3.06E-02 
PID_CIRCADIAN_PATHWAY 16 2 3.19E-02 
KEGG_METABOLISM_OF_XENOBIOTICS_BY_CYTOC
HROME_P450 70 3 3.27E-02 
KEGG_DRUG_METABOLISM_CYTOCHROME_P450 72 3 3.45E-02 
REACTOME_FATTY_ACID_TRIACYLGLYCEROL_AND
_KETONE_BODY_METABOLISM 168 4 3.76E-02 
PID_S1P_S1P1_PATHWAY 21 2 4.94E-02 




Table 2.5.  Gene sets that changed significantly, either similarly or differently, in response 
to smoke after both 1 and 5 days. The gene sets which are upregulated after 1 day and 
downregulated after 5 days of smoke involve mostly ECM-related processes. Those gene sets 
which are downregulated after 1 day and upregulated after 5 days of smoke involve primarily 
electron transport and oxidative phosphorylation pathways. The gene sets which are 
downregulated after both 1 and 5 days are exclusively associated with the immune response. The 
gene sets which are upregulated after both 1 and 5 days contain primarily those dealing with 
metabolism of small molecules. Red highlighting: upregulated gene sets. Blue highlighting: 




at 1 day 
Direction of 
Response 








REACTOME_SIGNALING_BY_PDGF 21.00 -12.64 








KEGG_MAPK_SIGNALING_PATHWAY 13.93 -9.64 
KEGG_MELANOMA 13.90 -7.44 
KEGG_FOCAL_ADHESION 13.55 -18.05 
REACTOME_HEMOSTASIS 13.18 -19.31 
NABA_ECM_GLYCOPROTEINS 12.79 -23.35 
PID_FAK_PATHWAY 12.21 -10.95 
PID_FOXM1_PATHWAY 12.10 -7.37 
REACTOME_AXON_GUIDANCE 11.98 -24.35 
NABA_CORE_MATRISOME 11.91 -27.24 
NABA_MATRISOME 11.28 -30.69 
PID_ER_NONGENOMIC_PATHWAY 11.08 -8.01 
PID_INTEGRIN1_PATHWAY 11.01 -22.65 
NABA_ECM_REGULATORS 10.81 -7.97 
PID_FGF_PATHWAY 10.47 -9.16 
PID_AVB3_INTEGRIN_PATHWAY 10.37 -16.30 
KEGG_GNRH_SIGNALING_PATHWAY 10.29 -8.97 



















KEGG_PROPANOATE_METABOLISM -14.67 14.93 
Down Down 









REACTOME_BETA_DEFENSINS -11.20 -8.38 




















BIOCARTA_LYM_PATHWAY -18.38 -19.42 





















BIOCARTA_P53HYPOXIA_PATHWAY 25.49 15.44 
REACTOME_XENOBIOTICS 24.97 32.03 












PID_TAP63_PATHWAY 21.99 15.78 
















REACTOME_GLUCURONIDATION 15.99 13.40 
PID_S1P_S1P1_PATHWAY 15.29 7.21 













KEGG_ABC_TRANSPORTERS 13.23 11.75 




































PID_HIF1_TFPATHWAY 11.25 12.95 





















Table 2.6.  Significant association of exposure-dependent changes in ECM gene sets from recent literature. GSA scores for gene 
sets derived from a recent review [95]. Bold text indicates that the association was significant at a q<0.05 threshold. 
 
  GSA Score for: 
Pathway Name: 
Exposure Genotype Sex 
1 day 
5 
days 1 day 
5 







-31.69 -17.71 3.03 62.47 37.01 
ECM_COLLAGENS_ERS_REVIEW_2017_EICKELBERG_WHITE 5.59 -16.33 -12.88 -0.09 36.07 21.14 
ECM_PROTEOGLYCANS_ERS_REVIEW_2017_EICKELBERG_
WHITE 










Table 2.7. Thresholds for gene set analysis significance in association testing with Canonical 
Pathways. These thresholds for minimally significant association scores were determined using 






 1 day 5 days 
Exposure 9.9 7.2 
Genotype 14.4 6.9 





Table 2.8. Thresholds for gene set analysis significance in association testing with ECM 
Pathways from a published literature review. These thresholds for minimally significant 
association scores were determined using 1000 sample permutations and identifying scores with 
q<0.05 FDR probability of random association. There was no threshold at which the association 
with genotype at 5 days is less than that of random chance.  
 
	 GSA Score 
Threshold 







Table 2.9. Summary of linear model testing. This table summarizes the numbers of significant 
genes found for genotype and sex using the linear model. The last row shows that no genes had a 
significantly better fit (q<0.05) using an interactive model that shows exposure-dependent 
responses in genotype and sex when compared with an additive linear model describing only 
independent changes between exposure, genotype, and sex. 
 
	
Number of genes 
significantly impacted 
(q<0.05) 
 1 day 5 days 
Genotype 1744 3178 
Sex 3107 214 





Figure 2.1.  Differences in the gene expression profile between smoke and sham exposure. 
A heatmap of all samples showing the expression levels of the pooled list of exposure-response 
genes that were significantly associated with exposure after 1 and/or 5 days and with a fold 
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change greater than +/-1.3. The color bar above the heatmap provides information about each 
sample. The samples subdivide into smoke- and sham-exposed samples, and then further 
subdivide by exposure duration (1 vs 5 days) in the smoke-exposed samples and by genotype 
(WT vs bENaC) in the sham-exposed animals. The genes were clustered into 5 clusters with 




Figure 2.2.  Breakdown of exposure-response genes by exposure duration and response to 
smoke. The Sankey diagram breaks down the genes in a hierarchical manner, and the area of the 
shape is proportional to the number of genes represented. Purple indicates results from 1 day of 
exposure; green indicates results from 5 days of exposure. (A): Sankey diagram showing the 
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proportion of exposure-response genes additionally affected by genotype and/or sex: 56% of the 
exposure-response genes at 1 day and 41% of the genes at 5 days are further modulated by 
genotype and/or sex. At 1 day, 70 of the exposure-response genes were also influenced by 
genotype and 93 genes were also influenced by sex, while 21 of the exposure-response genes 
were influenced independently by exposure, genotype, and sex (Fig 2A). After 5 days, 130 of the 
exposure-response genes were also influenced by genotype and 7 genes were also influenced by 
sex. Four genes were influenced independently by exposure, genotype, and sex. (B): Sankey 
diagram showing the proportion of exposure-response genes that are unique to each exposure 
duration (green and purple) compared to the proportion that responds significantly after both 1 
and 5 days (orange). 556 total exposure-response genes were identified at 1 and/or 5 days of 
smoke exposure. At 1 day, 330 exposure-genes were identified. 145 of these genes were uniquely 
significantly associated with the 1 day exposure, while 229 genes were also identified as 
significantly associated after 5 days. After 5 days, 347 exposure-genes were identified, 182 of 







Figure 2.3. Correlation between 1- and 5-day β coefficients in significant response genes for each variable.  The coefficient of 
correlation (“Corr”) is listed in the bottom right corner of the graph and reflects the tightness of fit of the observed b coefficients to a 
linear pattern. The slope of the best-fit regression line (“Slope of regression”, blue line) is also reported in the bottom right corner of 
the graph; the amount of deviation from the slope of the unity line (black dotted line) shows the amount of exposure-duration 
dependent response observed. The 95% confidence intervals for the regression line are outlined in blue, and the 95% prediction 
interval is outlined in grey. (A): Correlation of the exposure effects on expression in exposure-response genes at 1 and 5 days. Red 
dots indicate those genes which have significantly different responses at 1 and 5 days, as indicated by an interaction test. (B): 
Correlation of the genotype effects on expression in genotype-response genes at 1 and 5 days. (C): Correlation of the sex effects on 





Figure 2.4. IPA network analysis investigating NRF2’s role in exposure-response genes 
after 1- and/or 5-day exposures. The red and blue coloration of the molecules in the middle 
row corresponds to the expression level: red indicates that the gene is upregulated due to smoke, 
and blue indicates downregulation due to smoke. (A): The regulator effect network map showing 
the NRF2-mediated oxidative stress response. This regulator was strongly predicted to regulate 
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the pooled list of exposure-response genes significant after 1 and/or 5 days. The red and blue 
coloration reflects the expression level after 1 day of exposure. (B): The regulator effect network 
map showing the factors involved in regulating the cellular response, mediated by NFE2L2 
(NRF2), after 1 day of exposure. (C): The regulator effect network map showing the factors 







Figure 2.5. Robustness of gene expression data confirmed using published gene lists for bENaC mice. A heatmap showing the 
overlap between published genotype-response genes between bENaC and WT mice and our genotype-response gene lists after 1 day 
and 5 days of smoke exposure[71]. Genes that overlap with the published results are shown in yellow, while genes that were not found 
to be significantly associated with genotype in our study are shown in blue. The genotype-response gene lists from our study have 
significant overlap with the published lists. Our analysis also identified several new genes as differentially changed between bENaC 
and WT mice. 




Chapter 3: Conclusions and Future Directions 
3.1. Overview 
The overall goal of this dissertation was to better understand the effects of cigarette 
smoke on gene expression in the lung after 1 or 5 days of smoke exposure. The effects of acute 
doses of smoke have not been carefully characterized in the literature, and these exposure 
durations provided insight into the adaptation response of the lung soon after initiation of 
smoking. Since these studies cannot ethically be conducted in humans, this mouse study is of 
particular value to the scientific community.  
We characterized the gene expression in lung tissue after 1 and 5 days of smoke exposure 
and discovered hundreds of differentially expressed genes and gene sets that were changed in 
response to smoke at each exposure duration. Among those that were upregulated due to smoke 
after both 1 and 5 days of smoke were the oxidative stress-related gene sets and the xenobiotic 
response pathways. Genes that were downregulated after both exposure durations included the 
immune response.  
Gene sets which were upregulated after the first exposure to smoke but became 
downregulated by the fifth consecutive day of smoke exposure include the extracellular matrix 
biology-related gene sets, such as the matrisome. The list of gene sets which were downregulated 
after the first exposure but were upregulated by the fifth day of smoke exposure includes 
oxidative phosphorylation and electron transport-related pathways.  
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To ensure that the results presented are not due to technical artifacts, we checked for 
concordance with published literature for the genotype-response genes. Our results had 
significant overlap with the differentially expressed genes identified in the published study 
between bENaC mice and WT mice. Additionally, we confirmed that each mouse labeled as 
cigarette smoke-exposed had cotinine, a downstream metabolite of nicotine metabolism, present 
in the plasma.  
One interesting question remaining in this dataset is whether these exposure-response 
genes after 1 and 5 days of smoke compare with the differentially expressed genes identified in 
mice after six months of smoke exposure. A simple analysis looking at overlap between the gene 
lists in our study and a published study of chronically smoke-exposed mice[90] showed 
significant overlap. Although this analysis did not take into account differences in baseline gene 
expression due to the age differences of the mice, it is interesting to note the concordance 
between the gene lists, possibly indicating that similar processes are at work both acutely and 
chronically in the smoke-exposed lung.  
3.2. Genes and Pathways Upregulated in Response to Cigarette Smoke 
Genes involved in the oxidative stress response, as well as the xenobiotic response, were 
identified as significantly upregulated in smoke-exposed mice compared to sham-exposed mice 
after both 1 and 5 days of smoke. The upregulation of the oxidative stress response serves to 
counter-balance the increased burden of the oxidant load in the lung due to the oxide radicals 
present in cigarette smoke [104]. This is one of the mechanisms that the lung uses to cope with 
cigarette smoke exposure. The upregulation of these antioxidant response genes, such as Nqo1, 
provides insight into which genes are most responsive to cigarette smoke (Table 2.3). The 
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upregulation of the oxidative stress pathways from the curated literature further demonstrates 
how these processes are controlled and coordinated within the cell (Table 2.5).  
Nrf2, one of the main regulators of the oxidative stress response, was identified as a 
potential regulator of the cigarette smoke response (Fig 2.4). Based on the list of genes that were 
differentially expressed in response to smoke, Ingenuity Pathway Analysis predicted that Nrf2 is 
a transcription regulator. Nrf2 has been previously associated with the lung’s response to 
oxidative injury [114] and, specifically, cigarette smoke [102, 103]. Nqo1, an antioxidant 
response gene whose expression level is regulated by Nrf2, is significantly upregulated in 
response to cigarette smoke after 5 days of cigarette smoke exposure. When Nrf2 is deleted in 
mice that are exposed to cigarette smoke, they become more susceptible to extracellular matrix 
degradation and develop more severe emphysema than their WT counterparts exposed to an 
equivalent amount of cigarette smoke [102, 103]. Therefore, Nrf2 is likely involved in regulating 
the transcriptional response to cigarette smoke exposure.  
3.3. Genes and Pathways Downregulated in Response to Cigarette Smoke 
Gene sets representing all aspects of the immune response were downregulated after 
cigarette smoke exposure, including both innate and adaptive immune processes. The 
downregulation of the immune response after cigarette smoke exposure has been documented in 
other studies in both humans [104, 115] and mice [116] and is hypothesized to desensitize the 
immune surveillance system in the lung. By decreasing the sensitivity of the immune response in 
the lung, the oxidative bursts and extracellular matrix-remodeling roles of various immune cell 
populations is kept in check so as not to further damage the lung tissue environment [98, 104]. 
This downregulation is also attributed as the mechanism for the clinical observation that smokers 
have a higher incidence of respiratory diseases, such as pneumonia and influenza [117-119]. 
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Studies in the laboratory have also produced evidence of alveolar macrophages from smokers 
being less or incapable of killing bacterial pathogens [20, 26, 27]. These studies posit that the 
downregulation of the immune system begins early on in the smoking history of a patient, 
although persistent clinical symptoms do not develop until much later. The immune system 
downregulation at the gene level merits further study, at these acute time points and throughout 
the lifespan of the smoke-exposed mouse, to identify how and when changes in the immune 
system occur and what effect these changes have on the mouse’s ability to recover from 
respiratory challenges.  
Ccr3, a chemokine receptor hypothesized to be involved in the allergic airway response 
in humans [120], is one of the most downregulated genes involved in the immune response after 
5 days of cigarette smoke. In humans, this chemokine is highly expressed in eosinophils and 
basophils, which contribute to the innate immune response [121, 122]. Although several key 
chemokines such as Mip-2 and Lix are not significantly changed in response to cigarette smoke, 
it is clear that the immune response is involved in the lung’s response to cigarette smoke, and the 
mechanism of action merits further investigation.  
3.4. Genes and Pathways with Exposure Duration-dependent Responses to Cigarette Smoke 
Gene sets involving the extracellular matrix biology regulation and composition, 
including extracellular matrix glycoproteins, focal adhesion pathways, and others, were 
upregulated after the first exposure to smoke but downregulated by the fifth consecutive day of 
smoke exposure. The extracellular matrix composition and remodeling is a process actively 
involved in the development of cigarette smoke-associated lung disease. For example, chronic 
bronchitis involves the deposition of a stiffer extracellular matrix than in healthy lungs, with 
fibrotic lesions and tissue accumulating over the course of the disease [123-125]. Emphysema, 
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an important component of the pathology of COPD, involves destruction of the extracellular 
matrix, which results in gas exchange abnormalities [126]. A recent study showed that secreted 
proteins involved with the extracellular matrix were downregulated in ex vivo mouse lung tissue 
cultures exposed to cigarette smoke [113]. These studies provide insight into how the 
extracellular matrix response is regulated early on in the smoking history, and merits further 
study to understand how these changes affect the lung environment as the adaptation to cigarette 
smoke progresses as exposure duration increases. Understanding the regulation and response of 
the extracellular matrix throughout the course of a human’s smoking history would help 
clinicians identify the ideal treatment window to preventatively intervene to avoid irreversible 
damage to the lung tissue.  
Elastin, a component of the extracellular matrix, has significantly different expression 
when comparing smoke-exposed mice to their sham counterparts after both 1 and 5 days of 
smoke exposure. After 1 day, elastin is upregulated almost 1.5-fold in the smoke-exposed 
animals. However, by 5 days of exposure, the elastin gene has been downregulated 1.3-fold 
below the expression level of the sham-exposed animals. The differential regulation of this gene 
depending on the duration of the cigarette smoke exposure is intriguing, and could lead to either 
a fibrotic or destructive phenotype. The effect of the mRNA-level regulation of this and other 
ECM-related genes on the homeostasis of the lung tissue’s extracellular environment and the 
stiffness of the matrix merits further investigation. These studies indicate that the regulation of 
the extracellular matrix processes is a complicated and inter-related process that begins early on 
in a smoker’s history.  
Gene sets which are downregulated after the first exposure, but which become 
upregulated by the fifth consecutive day of cigarette smoke exposure, include some oxidative 
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phosphorylation and electron transport-related pathways. It has been well documented that the 
excess reactive oxygen species present in the lung tissue of a chronic smoker induces 
mitochondrial dysfunction, as the mitochondria are particularly susceptible to an imbalance in 
the reactive oxygen species present in the cell and surrounding microenvironment [127]. 
Mitochondrial dysfunction is considered a phenotype of COPD [101, 127]. Furthermore, a 
growing body of literature has been focused on characterizing the mechanisms of mitochondrial 
reprogramming after chronic cigarette smoke exposure, and the effects of alternative energy 
source utilization in this context [112]. Recent studies on the mitochondrial response to short-
term cigarette smoke exposure show that these changes can be reversible in certain contexts 
[101]. These studies contribute to this hypothesis by demonstrating the fast and responsive 
regulation of oxidative phosphorylation pathways during the lung’s adaptation to cigarette smoke 
exposure. Further studies quantifying the oxidative phosphorylation phenotype after 1 and 5 days 
of smoke exposure, as well as studies investigating the reversibility of these changes at the 
mRNA and protein levels, would further elucidate the role of mitochondrial energy production in 
the lung’s adaptive response to cigarette smoke.  
3.5. Summary of Gene Expression in Lung Tissue After 1 and 5 Days of Smoke Exposure and Future 
Directions 
Taken together, these data suggest that the lung responds to protect itself against 
damaging effects of cigarette smoke, particularly the oxidant burden it induces, by upregulating 
many anti-oxidant pathways and downregulating the inflammatory and immune responses, as 
well as protecting the lung matrix against damage and ineffective repair. We suggest that these 
changes are critical to chronic smokers, providing a basis for why lung damage takes many years 
to develop and a mechanistic understanding of their susceptibility to exacerbations, which are 
largely due to defects in inflammatory host defense. These studies suggest that studies of 
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individual cell types may prove fruitful. These future studies may focus on the changes in 
macrophage subpopulations or in subpopulations of airway and alveolar epithelial cells.  
3.6. Gene Expression in Lung Macrophages After 6 Months of Smoke 
Given the involvement of the immune response in the clinical phenotype of COPD and 
the specific evidence demonstrating lung macrophage involvement in lung tissue destruction and 
repair within the context of cigarette smoke-associated disease [20, 23-30, 32, 128, 129], we 
designed an experiment to identify and characterize the effects of cigarette smoke exposure on 
the various lung macrophage subpopulations. Briefly, three lung macrophage subtypes (alveolar 
macrophages, inflammatory macrophages, and interstitial macrophages) were isolated, as 
outlined in a previous publication [130], from male and female WT or bENaC mice exposed to 
six months of cigarette smoke. Gene expression was measured using a microarray, and similar 
analytical techniques were applied as in Chapter 2 of this thesis to determine the changes in gene 
expression in response to smoke within each macrophage subpopulation.  
Gene expression profiles are distinct and unique to each macrophage subpopulation (Fig 
5.1), when compared using a principal components analysis (PCA). PCA plots represent the 
overall differences due to gene expression in two-dimensional space by identifying the top 
sources of variation within a group of samples. A visible separation of subgroups of samples 
within the graph space indicates significant differences in gene expression. All three macrophage 
subpopulations show a distinct separation from each other and clustering within the 
subpopulation, indicating fundamental differences in the gene expression profile within each 
macrophage subpopulation that make the profile unique compared to the other subpopulations. 
Since the gene expression differences due to macrophage subpopulation are of such a large 
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magnitude and do not correlate with smoke exposure, we chose to proceed with all further 
analysis by analyzing each macrophage subpopulation individually.  
Therefore, we asked if smoke vs sham exposure correlated with the top principal 
components within each macrophage subpopulation (Fig 5.2). This method allows for an 
unbiased exploration of the data and the sources of variance within the gene expression profiles. 
The separation of smoke-exposed and sham-exposed samples within the plot for alveolar 
macrophages indicates that smoke exposure causes significant changes in the gene expression 
profile within this subpopulation. However, there is no visible separation between smoke- and 
sham-exposed samples in either the inflammatory or interstitial macrophage subpopulations.  
Next, we used a linear model to evaluate the effects of smoke exposure, genotype, and 
sex on gene expression within each macrophage subpopulation. Multiple rigorous analyses 
demonstrated that these three variables contributed independent changes to the gene expression 
profile, and that there were no sex-dependent or genotype-dependent changes due to smoke 
exposure within any of the macrophage subpopulations. Therefore, the variables of interest 
(smoke exposure, genotype, and sex) were modeled as independent variables in all downstream 
analyses. The number of genes significantly changed in response to each variable of interest 
(smoke exposure, genotype, and sex) with at least a 1.3-fold change were compiled into one 
chart (Fig 5.3). Based on these data and the PCA plots in Fig 5.2, we conclude that alveolar 
macrophages respond distinctly and uniquely to cigarette smoke exposure among the 
macrophage subpopulations measured. Therefore, further characterization of the gene expression 
responses to smoke exposure focused solely on the alveolar macrophages.  
To visualize the patterns of gene expression changes associated with exposure, the 
normalized log2 intensities of the 1980 exposure-response genes with at least a 1.3-fold change 
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in alveolar macrophages were compiled and clustered using k-means and hierarchical clustering 
(Fig 5.4). The samples segregated first into smoke- and sham-exposed, as expected. Genotype 
did not clearly segregate within either the smoke- or sham-exposed groups, and there was no 
clear segregation by sex.  
The 1980 exposure-response genes clustered into 6 clusters with distinct gene expression 
patterns using the k-means algorithm. Four clusters of genes were upregulated, while two 
clusters were downregulated. Analyses to identify associated pathways and gene sets using 
methods described in Chapter 2 of this thesis showed that among the downregulated genes in 
Cluster 1 are several genes involved in DNA repair and cell cycle regulation (Table 5.1). These 
changes have been previously identified in response to chronic smoke exposures in mice [39-41].  
Clusters 2 and 4 contain many genes known to be involved in the response and regulation 
of the immune system, which have been either downregulated (Cluster 2) or upregulated (Cluster 
4) in response to cigarette smoke (Table 5.1). Alveolar macrophages are an immune cell 
population that has many functions in immune surveillance and lung host defense.  The 
expression changes in genes and the signaling pathways that they regulate provide clear and 
valuable information about the signaling pathways and the functions of alveolar macrophages 
that are impacted by smoke.  Cigarette smoke-induced lung damage results in altered host 
defense and impaired responses to bacteria and viruses.  Our ongoing analysis of these changes 
in gene expression will contribute to pinpointing the signaling pathways and the resultant 
immune defects that lead to this altered host defense in alveolar macrophages. 
3.7. Ongoing Studies on Lung Macrophages Exposed to Chronic Smoke 
The role of each macrophage subpopulation in the lung and their response to cigarette 
smoke has not yet been clearly elucidated. Our studies aim to provide evidence that would fill 
	 	
 70 
this gap in knowledge for mouse models, which could produce hypotheses for directed testing in 
human lung tissue samples of chronic smokers. Lung tissue is heterogeneous by nature, and each 
cell population has a particular role in maintaining homeostasis. How that role is perturbed in the 
presence of cigarette smoke, and how the macrophage subpopulations adapt to that new 
environment, is an important question that will elucidate some of the mechanisms at play in 
cigarette smoke-associated chronic lung diseases.  
3.8. Future Directions 
This dissertation sought to increase the knowledge regarding the gene expression 
responses of the lung after acute (1 and 5 day) cigarette smoke exposure. The overall goal of the 
studies was to determine what changes, if any, were unique to each exposure duration, and to 
identify any exposure duration-dependent responses in the lung gene expression. We identified 
extracellular matrix biology-related processes as changing differently based on the exposure 
duration.  
In this dissertation, we did not examine the effects of these mRNA changes on the lung 
tissue architecture. We intend to determine how the extracellular matrix changes after six months 
of smoke exposure relate to those changes identified at these early time points, and quantify the 
effects on the lung tissue architecture. Some studies have identified these extracellular matrix 
changes as reversible with smoking cessation, and experiments designed to test that hypothesis 
would also merit further exploration.  
In this dissertation, we used a linear model to analyze the changes in gene expression in a 
complex study design with up to four variables. Computational tools exist which could model the 
differences in gene expression at various ages [131]. Although it was beyond the scope of this 
project, a careful and statistically rigorous analysis utilizing a tool specially designed for these 
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purposes could be used to model the changes seen at the acute exposure durations (1 and 5 days) 
and compare the projected changes with the observed gene expression profile after six month of 
smoke exposure.  
Finally, this dissertation looked at heterogeneous lung tissue samples composed of 
multiple cell populations after 1 and 5 days of cigarette smoke. Ongoing studies in the lab are 
investigating the role of lung macrophage subpopulations in the cigarette smoke response after 
six months. Future study could also include lung epithelial cell subpopulations at either the acute 
or chronic exposure durations, to examine the role of these subpopulations in the smoke response 




Table 3.1.  A summary of exposure-response genes in alveolar macrophages. The gene list 
from each k-means cluster (Figure 3.4) was individually analyzed for expression patterns and 
input into IPA to identify any enriched biological pathways. Key genes were identified as the top 
5 genes with the largest β coefficients. 
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Slc39a2 2.06   
Gm22645 1.58 
No pathways significantly 
enriched 
Ceacam16 1.42   




Granulocyte Adhesion and 
Diapedesis 
Itgam 3.03 




Innate and Adaptive Immune 
Cells 
Slc11a1 2.74 Complement System 









AW112010 -1.93   





Adgrl3 -2.67   
Trp53i11 -3.17 
No pathways significantly 
enriched 
Dnah11 -3.33   




Role of CHK Proteins in Cell 
Cycle Checkpoint Control 
Il1r1 -1.38 
Role of BRCA1 in DNA 
Damage Response 
Wfdc10 -1.43 













Cholesterol Biosynthesis I 
Awat1 4.91 
Cholesterol Biosynthesis II (via 
24,25-dihydrolanosterol) 
Arnt2 4.81 









Figure 3.1.  The largest differences in gene expression are due to macrophage 
subpopulation identity. Principal Component Analysis (PCA) plots showing the primary 
separation of samples by macrophage subpopulations. The first three principal components add 
to 35% of the total variation, indicating that differences in gene expression between macrophage 






Figure 3.2. Smoke exposure aligns with largest differences between samples in alveolar 
macrophages in PCA plot. The first two principal components are plotted for all samples within 
each macrophage subpopulation. The colored border around the graph indicates which 
macrophage subpopulation is plotted within. Samples (empty circles) are shaded according to 
whether the mouse received smoke (red) or sham (black) exposure for six months. (A): Alveolar 
macrophages show correlation between sample grouping and smoke exposure, indicating that 
smoke exposure could be responsible for the largest amount of variation within these samples. 
Sample grouping for (B) interstitial macrophages and (C) inflammatory macrophages does not 





Figure 3.3. Summary of differentially expressed genes in each macrophage subpopulation. 
The number of genes responding to each variable, arranged by the variable of interest and the 
macrophage subpopulation. Cigarette smoke has a distinct effect on alveolar macrophages that is 
not present in either interstitial or inflammatory macrophages. Few genes change due to either 







Figure 3.4.  Differences in the gene expression profile between smoke and sham exposure in 
alveolar macrophages. A heatmap of all samples showing the expression levels of the list of 
exposure-response genes that were significantly associated with exposure after 6 months of 
smoke in alveolar macrophages and with a fold change greater than +/-1.3. The color bar above 
the heatmap provides information about each sample. The samples subdivide into smoke- and 
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sham-exposed samples, as expected. The genes were clustered into 6 clusters with distinct 




APPENDIX 1: GSA SCORES FOR SIGNIFICANT EXPOSURE-ASSOCIATED GENE SETS 














































































































































































































































































































APPENDIX 2: GSA SCORES FOR SIGNIFICANT EXPOSURE-ASSOCIATED GENE SETS 
AFTER 5 DAYS OF EXPOSURE.  
 
























































































































































































































































































































































































































































































APPENDIX 3: RESULTS FOR ASSOCIATION OF EXPOSURE-RESPONSE GENES WITH 
FOLD CHANGE>1.3 AFTER 1 DAY OF EXPOSURE.  
This table includes the subset of all significant exposure-response genes with a fold change 
greater than +/-1.3 after 1 day of exposure, with the corresponding b coefficient, p value, and q 
value for association with exposure for each gene.  














RIKEN cDNA 1700094D03 
gene 
1700094
D03Rik -0.38 4.08E-11 3.28E-08 
NR_045301 
RIKEN cDNA 1810008I18 
gene 
1810008
I18Rik -0.46 1.03E-06 1.11E-04 
NM_001163473 
RIKEN cDNA 1810010H24 
gene 
1810010
H24Rik 0.60 3.66E-12 3.70E-09 
XM_006534098 
RIKEN cDNA 1810010H24 
gene 
1810010
H24Rik 0.82 1.23E-12 1.42E-09 
NM_001163145 
RIKEN cDNA 1810041L15 
gene 
1810041
L15Rik -0.44 3.33E-05 1.41E-03 
NM_028183 
RIKEN cDNA 1810062G17 
gene 
1810062
G17Rik -0.39 3.35E-06 2.66E-04 
ENSMUST0000
0154354 
RIKEN cDNA 2610507I01 
gene 
2610507
I01Rik -0.49 1.89E-07 3.07E-05 
NM_001145435 
RIKEN cDNA 4930451C15 
gene 
4930451
C15Rik -0.54 1.19E-07 2.14E-05 
NM_198642 
RIKEN cDNA 5031414D18 
gene 
5031414
D18Rik -0.42 8.19E-05 2.81E-03 
NM_001163539 
RIKEN cDNA 5430427O19 
gene 
5430427
O19Rik -0.41 6.84E-05 2.44E-03 
NR_028427 
RIKEN cDNA 5830416P10 
gene 
5830416
P10Rik -0.53 2.15E-05 1.03E-03 
NM_001166580 
RIKEN cDNA 8430408G22 
gene 
8430408
G22Rik -0.38 6.29E-04 1.20E-02 
NR_027961 
RIKEN cDNA 9130230L23 
gene 
9130230
L23Rik -0.43 1.89E-07 3.07E-05 
XR_401960 
RIKEN cDNA 9530034E10 
gene 
9530034
E10Rik 0.41 1.37E-03 2.07E-02 
NR_040271 
RIKEN cDNA A730046J19 
gene 
A730046
J19Rik -0.40 3.78E-05 1.54E-03 
NM_001007574 
RIKEN cDNA A830010M20 
gene 
A830010
M20Rik -0.40 2.81E-03 3.47E-02 
NM_013930 
aminoadipate-semialdehyde 
synthase Aass -0.38 5.66E-04 1.12E-02 
NM_001198794 cDNA sequence AB124611 
AB1246
11 -0.52 4.05E-05 1.63E-03 
NM_001166556 
ATP-binding cassette, sub-
family A (ABC1), member 6 Abca6 0.38 8.74E-04 1.51E-02 
NM_023732 
ATP-binding cassette, sub-
family B (MDR/TAP), member 





family C (CFTR/MRP), 
member 1 Abcc1 0.39 3.05E-09 1.22E-06 
NM_001161667 
acyl-Coenzyme A oxidase 2, 
branched chain Acox2 0.44 2.89E-08 7.42E-06 
NM_019807 acid phosphatase, prostate Acpp 0.52 3.63E-09 1.37E-06 
NM_001142804 
acyl-CoA synthetase short-
chain family member 3 Acss3 0.56 5.62E-07 7.01E-05 
NM_001033877 
a disintegrin-like and 
metallopeptidase (reprolysin 
type) with thrombospondin 
type 1 mo 
Adamts1
7 0.61 7.06E-04 1.28E-02 
NM_009626 
alcohol dehydrogenase 7 
(class IV), mu or sigma 
polypeptide Adh7 2.26 9.50E-24 7.45E-20 
NM_009644 
aryl-hydrocarbon receptor 
repressor Ahrr 0.47 3.09E-09 1.22E-06 
ENSMUST0000
0038406 
aldo-keto reductase family 1, 
member B8 Akr1b8 0.68 1.93E-10 1.14E-07 
NM_134072 
aldo-keto reductase family 1, 
member C14 Akr1c14 0.53 1.65E-07 2.76E-05 
NM_001112725 
aldehyde dehydrogenase 
family 3, subfamily A1 Aldh3a1 2.84 1.34E-26 1.40E-22 
NM_009676 aldehyde oxidase 1 Aox1 0.58 4.36E-16 1.42E-12 
NM_175391 apolipoprotein L 7c Apol7c 0.76 5.87E-05 2.16E-03 
NM_177828 
Rho guanine nucleotide 
exchange factor (GEF) 37 Arhgef37 -0.68 8.11E-04 1.43E-02 
NM_001284192 artemin Artn 0.78 1.11E-08 3.41E-06 
NM_153778 atonal homolog 8 (Drosophila) Atoh8 0.38 9.86E-07 1.09E-04 
NM_001290469 
ATPase, Na+/K+ transporting, 
alpha 3 polypeptide Atp1a3 -0.71 2.53E-04 6.16E-03 
ENSMUST0000
0101044 
ATPase, Ca++ transporting, 
plasma membrane 2 Atp2b2 0.53 3.89E-06 2.99E-04 
NM_026922 
ATPase, Ca++ transporting, 
type 2C, member 2 Atp2c2 -0.51 1.42E-06 1.38E-04 
NM_134157 
ATPase, H+ transporting, 
lysosomal V1 subunit B1 
Atp6v1b
1 -0.64 3.13E-09 1.22E-06 
NM_001080935 
RIKEN cDNA B230217C12 
gene 
B230217





9 B3gnt9 -0.38 5.98E-07 7.29E-05 
NR_015457 
RIKEN cDNA B430010I23 
gene 
B430010
I23Rik -0.72 1.51E-11 1.31E-08 
NM_001033350 
B cell scaffold protein with 
ankyrin repeats 1 Bank1 -0.52 2.44E-04 6.00E-03 
NM_007539 bradykinin receptor, beta 1 Bdkrb1 0.58 1.60E-05 8.43E-04 
NM_009747 bradykinin receptor, beta 2 Bdkrb2 0.52 2.51E-06 2.12E-04 
ENSMUST0000
0037399 
biliverdin reductase B (flavin 




complement component 1, r 




(putative) Cand2 -0.40 5.24E-05 1.99E-03 
NM_173047 carbonyl reductase 3 Cbr3 1.83 3.47E-22 2.17E-18 
NM_001081665 
coiled-coil domain containing 
129 Ccdc129 -1.15 4.55E-13 5.94E-10 
NM_009827 cholecystokinin A receptor Cckar -0.75 6.33E-15 1.42E-11 
ENSMUST0000
0170878 CD180 antigen Cd180 -0.53 1.34E-06 1.32E-04 
NM_018729 
CD244 natural killer cell 
receptor 2B4 Cd244 -0.48 4.66E-04 9.62E-03 
NM_172050 CD300e antigen Cd300e -0.64 1.88E-05 9.46E-04 
NM_199221 
CD300 antigen like family 
member B Cd300lb -0.58 1.75E-03 2.50E-02 
NM_145437 
CD300 molecule-like family 
member d Cd300ld -0.65 9.85E-05 3.18E-03 
NM_183294 
cyclin-dependent kinase-like 1 
(CDC2-related kinase) Cdkl1 -0.48 9.32E-08 1.79E-05 
NM_007669 
cyclin-dependent kinase 
inhibitor 1A (P21) Cdkn1a 0.48 1.64E-05 8.55E-04 
NM_144930 carboxylesterase 1F Ces1f 0.79 5.69E-11 4.25E-08 
NM_021456 carboxylesterase 1G Ces1g 2.07 5.19E-15 1.25E-11 
XM_006544349 carboxylesterase 1H Ces1h 0.57 5.14E-09 1.79E-06 
NM_018778 claudin 8 Cldn8 -0.62 7.73E-11 5.38E-08 
NM_177686 
C-type lectin domain family 12, 
member a Clec12a -0.76 1.15E-08 3.50E-06 
NM_199311 
C-type lectin domain family 4, 
member a1 Clec4a1 -0.69 8.40E-05 2.86E-03 
NM_001204241 
C-type lectin domain family 4, 
member a3 Clec4a3 -0.43 3.03E-03 3.66E-02 
NM_007724 
cyclic nucleotide gated 
channel alpha 2 Cnga2 0.54 2.02E-07 3.19E-05 
NR_002845 
coatomer protein complex, 
subunit gamma 2, opposite 
strand 2 
Copg2os
2 0.59 5.05E-07 6.48E-05 
NM_007758 complement receptor 2 Cr2 -0.49 4.03E-04 8.71E-03 
NM_007771 
cryptochrome 1 (photolyase-
like) Cry1 0.44 8.70E-07 9.95E-05 
NM_001012477 
chemokine (C-X-C motif) 
ligand 12 Cxcl12 -0.39 1.06E-05 6.30E-04 
NM_007807 
cytochrome b-245, beta 
polypeptide Cybb -0.39 1.01E-03 1.67E-02 
NM_001136059 
cytochrome P450, family 1, 
subfamily a, polypeptide 1 Cyp1a1 4.11 1.01E-17 4.52E-14 
NM_009994 
cytochrome P450, family 1, 
subfamily b, polypeptide 1 Cyp1b1 3.16 1.47E-30 4.60E-26 
NM_001177713 
cytochrome P450, family 26, 




cytochrome P450, family 2, 
subfamily a, polypeptide 4 Cyp2a4 0.43 6.83E-04 1.25E-02 
ENSMUST0000
0005685 
cytochrome P450, family 2, 
subfamily a, polypeptide 5 Cyp2a5 0.46 2.62E-04 6.33E-03 
NM_134127 
cytochrome P450, family 4, 
subfamily f, polypeptide 15 Cyp4f15 -0.73 2.86E-07 4.28E-05 
NM_024444 
cytochrome P450, family 4, 
subfamily f, polypeptide 18 Cyp4f18 -0.60 2.77E-04 6.60E-03 
NM_177307 
cytochrome P450, family 4, 
subfamily f, polypeptide 39 Cyp4f39 0.79 3.23E-09 1.24E-06 
NM_026384 
diacylglycerol O-
acyltransferase 2 Dgat2 -0.42 5.97E-04 1.16E-02 
NM_030150 
DEXH (Asp-Glu-X-His) box 
polypeptide 58 Dhx58 -0.40 2.47E-05 1.14E-03 
NM_010050 
deiodinase, iodothyronine, 
type II Dio2 0.54 1.56E-03 2.29E-02 
NM_001024474 
DIRAS family, GTP-binding 
RAS-like 2 Diras2 -0.39 3.20E-04 7.33E-03 
NM_001252070 
dynein, axonemal, heavy chain 
7A Dnah7a -0.42 1.27E-04 3.81E-03 
NM_013739 docking protein 3 Dok3 -0.40 2.19E-05 1.04E-03 
NR_015502 
RIKEN cDNA E030003E18 
gene 
E030003
E18Rik 0.47 9.33E-06 5.74E-04 
NR_045343 
RIKEN cDNA E030044B06 
gene 
E030044
B06Rik -0.41 6.51E-09 2.15E-06 
NM_001195036 
epithelial cell transforming 
sequence 2 oncogene-like Ect2l -0.41 6.41E-07 7.73E-05 
NM_010104 endothelin 1 Edn1 0.55 1.14E-06 1.19E-04 
AK002956 
endogenous sequence related 
to the Duplan murine retrovirus Edv 0.39 9.81E-05 3.17E-03 
NM_001289925 early growth response 3 Egr3 -0.38 7.75E-04 1.38E-02 
NM_020578 EH-domain containing 3 Ehd3 0.44 7.01E-06 4.62E-04 
NM_025499 
EP300 interacting inhibitor of 
differentiation 3 Eid3 0.85 1.60E-10 1.01E-07 
NM_001163131 E74-like factor 3 Elf3 0.52 3.16E-07 4.62E-05 
NM_007925 elastin Eln 0.54 2.16E-04 5.57E-03 
NM_145158 elastin microfibril interfacer 2 Emilin2 -0.56 1.59E-03 2.32E-02 
NM_139138 
EGF-like module containing, 
mucin-like, hormone receptor-
like sequence 4 Emr4 -1.12 2.52E-09 1.03E-06 
NM_178676 
ectonucleoside triphosphate 
diphosphohydrolase 3 Entpd3 0.52 1.84E-07 3.02E-05 
NM_001026214 
ectonucleoside triphosphate 
diphosphohydrolase 5 Entpd5 0.67 6.67E-11 4.86E-08 
NM_029325 epididymal peptidase inhibitor Eppin 0.49 1.23E-04 3.72E-03 
NM_029495 
epithelial stromal interaction 1 
(breast) Epsti1 -0.40 4.07E-05 1.64E-03 
ENSMUST0000
0098496 glutamate rich 3 Erich3 0.52 8.70E-08 1.74E-05 
ENSMUST0000





molecule 1 Esm1 -0.42 2.98E-04 6.94E-03 
NM_001038658 
Fas apoptotic inhibitory 
molecule 2 Faim2 -0.41 2.29E-04 5.77E-03 
NM_183187 
family with sequence similarity 
107, member A 
Fam107
a 0.75 5.61E-06 3.90E-04 
NM_001080814 
FAT tumor suppressor 
homolog 3 (Drosophila) Fat3 -0.39 2.45E-04 6.02E-03 
NM_001199632 
F-box and leucine-rich repeat 
protein 13 Fbxl13 -0.44 5.90E-07 7.26E-05 
NM_001253737 
Fc receptor, IgE, low affinity II, 
alpha polypeptide Fcer2a -0.65 4.06E-04 8.72E-03 
NM_010186 Fc receptor, IgG, high affinity I Fcgr1 -0.52 2.66E-03 3.34E-02 
NM_181748 free fatty acid receptor 4 Ffar4 0.50 4.24E-06 3.16E-04 
NM_001271616 
fibroblast growth factor binding 
protein 1 Fgfbp1 0.72 1.96E-07 3.12E-05 
NM_010208 
Gardner-Rasheed feline 
sarcoma viral (Fgr) oncogene 
homolog Fgr -0.53 1.43E-03 2.16E-02 
NM_010220 FK506 binding protein 5 Fkbp5 0.65 1.80E-05 9.17E-04 
NM_010235 fos-like antigen 1 Fosl1 0.57 3.63E-04 8.09E-03 
NM_008239 forkhead box Q1 Foxq1 0.42 1.03E-06 1.11E-04 
NM_177059 follistatin-like 4 Fstl4 0.45 6.95E-05 2.47E-03 
ENSMUST0000
0167243 
glutamate decarboxylase 1, 





e 15 Galnt15 0.53 2.28E-03 3.01E-02 
NM_010295 
glutamate-cysteine ligase, 
catalytic subunit Gclc 1.06 1.77E-12 1.91E-09 
NM_008129 
glutamate-cysteine ligase, 
modifier subunit Gclm 1.19 1.06E-21 5.56E-18 
NM_001285457 
glial cell line derived 
neurotrophic factor family 
receptor alpha 1 Gfra1 -0.45 7.15E-08 1.51E-05 
NM_008115 
glial cell line derived 
neurotrophic factor family 
receptor alpha 2 Gfra2 -0.54 3.84E-07 5.32E-05 
NM_008125 gap junction protein, beta 2 Gjb2 0.89 5.69E-09 1.96E-06 
ENSMUST0000
0087884 predicted pseudogene 10212 
Gm1021
2 0.38 2.07E-04 5.43E-03 
ENSMUST0000
0095186 predicted gene 10309 
Gm1030
9 0.48 2.54E-05 1.16E-03 
NM_001122660 predicted gene 10639 
Gm1063
9 0.48 3.72E-08 9.25E-06 
ENSMUST0000
0151643 predicted gene 12214 
Gm1221
4 -0.39 7.10E-05 2.52E-03 
NM_001135115 predicted gene 12250 
Gm1225
0 -0.49 1.46E-03 2.19E-02 
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XR_375897 predicted gene 12474 
Gm1247
4 -0.76 3.74E-09 1.38E-06 
NM_001081284 predicted gene 12695 
Gm1269
5 -0.68 6.02E-09 2.05E-06 
ENSMUST0000
0156081 predicted gene 12840 
Gm1284
0 0.41 2.13E-07 3.30E-05 
XR_402166 predicted gene 13056 
Gm1305
6 -0.41 9.01E-05 3.01E-03 
XR_377237 predicted gene 15411 
Gm1541
1 -0.39 4.52E-06 3.30E-04 
NR_045598 predicted gene 15706 
Gm1570
6 -0.39 1.72E-06 1.60E-04 
ENSMUST0000
0141700 predicted gene 15987 
Gm1598
7 -0.39 3.33E-03 3.91E-02 
ENSMUST0000
0130872 predicted gene 17216 
Gm1721
6 0.42 9.78E-05 3.17E-03 
NR_045322 predicted gene, 19557 
Gm1955
7 0.53 2.96E-07 4.42E-05 
XR_378466 predicted gene, 19950 
Gm1995
0 0.52 8.10E-08 1.64E-05 
AK079756 predicted gene, 19951 
Gm1995
1 -0.94 2.10E-05 1.01E-03 
XR_105484 predicted gene, 20016 
Gm2001
6 -0.44 1.81E-06 1.66E-04 
AK172267 predicted gene, 21188 
Gm2118
8 -0.54 3.84E-04 8.40E-03 
ENSMUST0000
0102085 predicted gene, 22137 
Gm2213
7 0.41 1.21E-03 1.91E-02 
ENSMUST0000
0158269 predicted gene, 22520 
Gm2252
0 0.45 5.41E-04 1.08E-02 
ENSMUST0000
0082925 predicted gene, 24524 
Gm2452
4 -0.60 9.78E-05 3.17E-03 
ENSMUST0000
0158937 predicted gene, 24666 
Gm2466
6 0.48 1.18E-06 1.20E-04 
ENSMUST0000
0158857 predicted gene, 24741 
Gm2474
1 -0.43 6.07E-04 1.17E-02 
ENSMUST0000
0181901 predicted gene, 26760 
Gm2676
0 -0.40 5.08E-05 1.95E-03 
NR_046069 predicted gene 2848 Gm2848 -0.38 3.60E-03 4.13E-02 
NM_001243092 predicted gene 3776 Gm3776 1.85 6.22E-17 2.44E-13 
NM_001243039 predicted gene 4070 Gm4070 -0.38 1.93E-06 1.72E-04 
NR_003967 
GTPase, very large interferon 
inducible 1 pseudogene Gm4759 -0.41 1.32E-03 2.02E-02 
ENSMUST0000
0095071 predicted gene 8074 Gm8074 0.63 9.15E-08 1.77E-05 
NM_001164202 predicted gene 8369 Gm8369 -0.42 2.93E-03 3.58E-02 
XR_378400 predicted gene 8995 Gm8995 -0.45 4.02E-07 5.52E-05 
NM_001076679 predicted gene 9733 Gm9733 -1.03 2.14E-04 5.55E-03 
ENSMUST0000
0066742 predicted gene 9930 Gm9930 0.49 1.64E-05 8.56E-04 
NM_001285916 
geminin coiled-coil domain 




guanine nucleotide binding 
protein, alpha O Gnao1 0.43 8.35E-07 9.62E-05 
NM_181754 
G protein-coupled receptor 
141 Gpr141 -0.75 6.82E-04 1.25E-02 
NM_007412 
G protein-coupled receptor 
182 Gpr182 0.55 4.95E-07 6.41E-05 
NM_008152 G-protein coupled receptor 65 Gpr65 -0.45 2.01E-03 2.76E-02 
NM_001291111 glutathione synthetase Gss 0.42 1.79E-08 4.83E-06 
NM_008181 
glutathione S-transferase, 
alpha 1 (Ya) Gsta1 1.63 2.17E-15 6.18E-12 
NM_010357 
glutathione S-transferase, 
alpha 4 Gsta4 0.62 1.26E-11 1.16E-08 
NM_010362 
glutathione S-transferase 
omega 1 Gsto1 0.60 4.27E-14 7.05E-11 
NM_013541 glutathione S-transferase, pi 1 Gstp1 0.45 2.21E-09 9.38E-07 
NM_181796 glutathione S-transferase, pi 2 Gstp2 0.46 6.97E-12 6.62E-09 
NM_001033978 
histocompatibility 2, class II 
antigen E beta2 H2-Eb2 -0.54 4.12E-05 1.65E-03 
NM_010389 
histocompatibility 2, O region 
beta locus H2-Ob -0.43 3.69E-04 8.17E-03 
NM_025325 
3-hydroxyanthranilate 3,4-
dioxygenase Haao -0.41 1.85E-04 5.00E-03 
NM_008230 histidine decarboxylase Hdc -0.57 2.91E-05 1.28E-03 
NM_010442 heme oxygenase (decycling) 1 Hmox1 1.76 1.14E-14 2.24E-11 
NM_152803 heparanase Hpse -0.57 2.08E-06 1.84E-04 
NM_197944 
hematopoietic SH2 domain 
containing Hsh2d -0.49 1.19E-05 6.86E-04 
NM_010478 heat shock protein 1B Hspa1b 1.05 6.89E-04 1.26E-02 
NM_013559 
heat shock 105kDa/110kDa 
protein 1 Hsph1 0.56 1.79E-04 4.90E-03 
NM_008329 interferon activated gene 204 Ifi204 -0.98 1.72E-04 4.80E-03 
NM_029803 
interferon, alpha-inducible 
protein 27 like 2A Ifi27l2a -0.48 3.33E-04 7.55E-03 
NM_001033632 
interferon induced 
transmembrane protein 6 Ifitm6 -1.14 6.84E-05 2.44E-03 
ENSMUST0000
0129913 
insulin-like growth factor 2 




diversity 5-8 Ighd5-8 -0.41 2.05E-03 2.81E-02 
ENSMUST0000
0103407 
immunoglobulin kappa joining 




variable 4-63 Igkv4-63 -0.54 4.27E-04 9.06E-03 
NM_030691 
immunoglobulin superfamily, 
member 6 Igsf6 -0.52 5.92E-04 1.15E-02 
NM_001136067 
inhibitor of kappaB kinase 
gamma Ikbkg 0.39 1.99E-10 1.15E-07 
NM_008348 interleukin 10 receptor, alpha Il10ra -0.44 1.08E-06 1.15E-04 
NM_001252600 interferon regulatory factor 7 Irf7 -0.39 9.45E-04 1.59E-02 
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NM_010576 integrin alpha 4 Itga4 -0.44 1.09E-08 3.38E-06 
NM_001253872 integrin alpha L Itgal -0.46 1.67E-07 2.79E-05 
NM_001082960 integrin alpha M Itgam -0.46 3.64E-03 4.16E-02 
NM_001164268 kalirin, RhoGEF kinase Kalrn 0.59 3.44E-13 4.69E-10 
NM_172872 
KN motif and ankyrin repeat 
domains 4 Kank4 0.39 1.08E-05 6.35E-04 
NM_001111331 
Kv channel interacting protein 
3, calsenilin Kcnip3 0.67 1.12E-07 2.04E-05 
NM_008430 
potassium channel, subfamily 
K, member 1 Kcnk1 0.40 2.03E-07 3.19E-05 
NM_001122733 kit oncogene Kit 0.44 9.46E-09 3.00E-06 
NM_001164493 kelch-like 29 Klhl29 0.46 1.11E-05 6.53E-04 
NM_001170851 
killer cell lectin-like receptor, 
subfamily A, member 2 Klra2 -0.59 1.90E-05 9.49E-04 
NM_008469 keratin 15 Krt15 0.49 9.46E-05 3.11E-03 
NM_001113474 
leukocyte-associated Ig-like 
receptor 1 Lair1 -0.51 3.58E-05 1.49E-03 
NM_008480 laminin, alpha 1 Lama1 0.79 1.34E-07 2.35E-05 




















641542 -0.43 3.32E-03 3.90E-02 
ENSMUST0000
0103529 Ig heavy chain V region 
LOC238
440 -0.64 4.30E-03 4.63E-02 
XR_386789 uncharacterized LOC73899 
LOC738
99 -0.53 6.29E-04 1.20E-02 




acyltransferase) Lrat -0.74 5.94E-07 7.28E-05 
NM_001080926 
low density lipoprotein 
receptor-related protein 8, 
apolipoprotein e receptor Lrp8 0.72 9.92E-09 3.11E-06 
NM_028977 
leucine rich repeat containing 
17 Lrrc17 -0.48 1.30E-05 7.29E-04 
NM_146117 
leucine rich repeat containing 
26 Lrrc26 -0.59 1.59E-08 4.54E-06 
NM_010734 leukocyte specific transcript 1 Lst1 -0.48 7.80E-04 1.38E-02 
NM_001099217 
lymphocyte antigen 6 complex, 
locus C2 Ly6c2 -0.38 8.18E-04 1.43E-02 
NM_010745 lymphocyte antigen 86 Ly86 -0.47 2.62E-05 1.19E-03 
NM_027990 
LY6/PLAUR domain 




lymphatic vessel endothelial 
hyaluronan receptor 1 Lyve1 0.52 4.03E-06 3.04E-04 
NM_010755 
v-maf musculoaponeurotic 
fibrosarcoma oncogene family, 
protein F (avian) Maff 0.52 1.36E-05 7.53E-04 
NM_145532 
mal, T cell differentiation 
protein-like Mall 0.51 4.91E-08 1.16E-05 
NM_016693 
mitogen-activated protein 
kinase kinase kinase 6 Map3k6 0.56 4.92E-05 1.89E-03 
NM_001162904 
transformed mouse 3T3 cell 
double minute 1 Mdm1 -0.40 1.92E-06 1.72E-04 
NM_001271375 
mast cell immunoglobulin like 
receptor 1 Milr1 -0.42 7.70E-04 1.37E-02 
NR_029541 microRNA 126a Mir126a 0.42 2.34E-03 3.04E-02 
NR_029742 microRNA 26a-1 Mir26a-1 0.41 3.49E-03 4.04E-02 
NM_001033450 
myeloid cell nuclear 
differentiation antigen Mnda -0.53 9.70E-04 1.63E-02 
NM_001081287 
membrane protein, 
palmitoylated 7 (MAGUK p55 
subfamily member 7) Mpp7 0.40 5.16E-06 3.69E-04 
XM_006527251 
membrane-spanning 4-
domains, subfamily A, member 
4C Ms4a4c -0.55 1.59E-05 8.39E-04 
NM_028595 
membrane-spanning 4-
domains, subfamily A, member 
6C Ms4a6c -0.45 3.55E-03 4.08E-02 
NM_013602 metallothionein 1 Mt1 0.54 1.51E-12 1.69E-09 





methenyltetrahydrofolate cycl Mthfd2 0.46 2.42E-04 5.98E-03 
NM_001145874 mucin 20 Muc20 -0.43 4.31E-06 3.20E-04 
NM_010892 
NIMA (never in mitosis gene 
a)-related expressed kinase 2 Nek2 -0.46 3.61E-06 2.82E-04 
NM_153408 
neuralized homolog 3 homolog 
(Drosophila) Neurl3 0.39 1.13E-06 1.19E-04 
NM_010927 
nitric oxide synthase 2, 
inducible Nos2 -0.58 9.04E-08 1.77E-05 
NM_010930 
nephroblastoma 
overexpressed gene Nov 0.39 3.20E-08 8.09E-06 
NM_001039181 natriuretic peptide receptor 3 Npr3 0.59 9.48E-05 3.11E-03 
NM_008706 
NAD(P)H dehydrogenase, 
quinone 1 Nqo1 2.87 3.91E-27 6.12E-23 
XM_006509086 neuregulin 1 Nrg1 0.52 3.61E-05 1.50E-03 
NM_025539 
nudix (nucleoside diphosphate 
linked moiety X)-type motif 2 Nudt2 -0.44 1.43E-07 2.48E-05 
NM_011852 
2-5 oligoadenylate synthetase 
1G Oas1g -0.54 2.20E-03 2.94E-02 




oxidative stress induced 
growth inhibitor 1 Osgin1 1.02 3.41E-14 6.29E-11 
NM_011061 
peptidyl arginine deiminase, 
type IV Padi4 -0.51 1.34E-04 3.98E-03 
NM_011995 
piccolo (presynaptic cytomatrix 
protein) Pclo -0.41 1.03E-07 1.94E-05 
NM_008817 paternally expressed 3 Peg3 0.62 3.39E-07 4.80E-05 
NR_023846 Peg3 opposite strand Peg3os 0.40 2.64E-04 6.36E-03 
NM_001081274 
phosphogluconate 
dehydrogenase Pgd 0.41 3.07E-08 7.81E-06 
NM_172603 PHD finger protein 11A Phf11a -0.42 1.16E-03 1.85E-02 
NM_001164327 PHD finger protein 11B Phf11b -0.39 1.92E-04 5.14E-03 
NM_001252568 
phytanoyl-CoA dioxygenase 
domain containing 1 Phyhd1 0.52 2.29E-09 9.58E-07 
NM_011082 
polymeric immunoglobulin 
receptor Pigr -0.59 6.44E-05 2.33E-03 
NM_001024932 
paired immunoglobin-like type 
2 receptor beta 2 Pilrb2 -0.50 1.97E-04 5.23E-03 
ENSMUST0000
0031264 placenta-specific 8 Plac8 -0.65 1.32E-04 3.94E-03 
NM_025806 
phospholipase B domain 
containing 1 Plbd1 -0.42 4.13E-06 3.11E-04 
NM_001145830 phospholipase C, beta 1 Plcb1 -0.74 5.84E-13 7.33E-10 
NM_178911 
phospholipase D family, 
member 4 Pld4 -0.44 1.20E-05 6.88E-04 
NM_026784 phosphomevalonate kinase Pmvk 0.65 1.34E-07 2.35E-05 
NM_008855 protein kinase C, beta Prkcb -0.47 3.52E-05 1.47E-03 
NM_177420 
phosphoserine 
aminotransferase 1 Psat1 0.48 1.73E-06 1.60E-04 
NM_011196 
prostaglandin E receptor 3 
(subtype EP3) Ptger3 -0.40 1.66E-03 2.40E-02 
NM_011198 
prostaglandin-endoperoxide 
synthase 2 Ptgs2 1.37 2.17E-10 1.21E-07 
NM_025760 
protein tyrosine phosphatase-
like A domain containing 2 Ptplad2 -0.54 4.63E-09 1.67E-06 
NM_001164401 
protein tyrosine phosphatase, 
receptor type, O Ptpro -0.39 2.68E-04 6.44E-03 
NM_175026 
pyrin and HIN domain family, 
member 1 Pyhin1 -0.50 1.00E-04 3.21E-03 
NM_001024945 
quiescin Q6 sulfhydryl oxidase 
1 Qsox1 0.42 6.45E-09 2.15E-06 
NM_019511 
receptor (calcitonin) activity 
modifying protein 3 Ramp3 0.59 4.94E-09 1.76E-06 
NM_001015046 
RAP1 GTPase activating 
protein 2 
Rap1gap
2 -0.41 7.81E-07 9.06E-05 
NM_001289761 retinoic acid receptor, beta Rarb -0.43 1.43E-04 4.18E-03 
NM_181596 resistin like gamma Retnlg -0.66 2.61E-03 3.30E-02 
NM_001195748 
regulator of G-protein 




regulator of G-protein signaling 
9 Rgs9 0.55 5.56E-08 1.27E-05 
NM_011311 
S100 calcium binding protein 
A4 S100a4 -0.52 5.09E-04 1.03E-02 
NM_053190 
sphingosine-1-phosphate 
receptor 5 S1pr5 -0.48 7.58E-05 2.64E-03 
NM_018732 
sodium channel, voltage-
gated, type III, alpha Scn3a -0.43 1.01E-05 6.09E-04 
NM_172710 
sel-1 suppressor of lin-12-like 
3 (C. elegans) Sel1l3 0.46 4.28E-03 4.62E-02 
ENSMUST0000
0090839 selenium binding protein 1 
Selenbp
1 0.71 3.35E-13 4.69E-10 
NM_019414 selenium binding protein 2 
Selenbp
2 0.61 1.56E-09 7.07E-07 
NM_001164059 selectin, lymphocyte Sell -0.49 1.03E-06 1.11E-04 
NM_027997 
serine (or cysteine) peptidase 
inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin) Serpina9 0.77 5.91E-10 3.14E-07 
NM_001160307 
serine (or cysteine) peptidase 
inhibitor, clade B (ovalbumin), 
member 10 
Serpinb1
0 -1.05 1.81E-06 1.66E-04 
NM_009170 sonic hedgehog Shh 0.77 2.13E-11 1.81E-08 
NM_001159419 
SID1 transmembrane family, 
member 1 Sidt1 -0.39 1.46E-04 4.24E-03 
NM_001173460 
signal-regulatory protein beta 
1B Sirpb1b -0.51 3.71E-03 4.22E-02 
NM_001010834 
solute carrier family 10 
(sodium/bile acid cotransporter 
family), member 5 Slc10a5 -0.79 1.08E-10 7.33E-08 
NM_013612 
solute carrier family 11 
(proton-coupled divalent metal 
ion transporters), member 1 Slc11a1 -0.50 2.15E-03 2.89E-02 
NM_018861 
solute carrier family 1 
(glutamate/neutral amino acid 
transporter), member 4 Slc1a4 0.69 2.29E-11 1.89E-08 
NM_011397 
solute carrier family 23 
(nucleobase transporters), 
member 1 Slc23a1 -0.45 6.52E-10 3.41E-07 
NM_022317 
solute carrier family 28 
(sodium-coupled nucleoside 
transporter), member 3 Slc28a3 -0.44 8.37E-05 2.86E-03 
NM_027052 
solute carrier family 38, 
member 4 Slc38a4 0.40 3.27E-04 7.45E-03 
NM_008135 
solute carrier family 6 
(neurotransmitter transporter, 
glycine), member 9 Slc6a9 0.40 6.30E-08 1.37E-05 
NM_011990 
solute carrier family 7 (cationic 
amino acid transporter, y+ 
system), member 11 Slc7a11 3.65 2.64E-15 6.91E-12 
NM_011404 
solute carrier family 7 (cationic 
amino acid transporter, y+ 




solute carrier organic anion 
transporter family, member 
1a5 Slco1a5 -0.39 3.87E-06 2.98E-04 
NM_011407 schlafen 1 Slfn1 -0.66 3.72E-04 8.22E-03 
NM_020519 
secreted Ly6/Plaur domain 
containing 1 Slurp1 -0.63 1.33E-05 7.41E-04 
NM_144918 
SET and MYND domain 
containing 5 Smyd5 -0.40 2.31E-04 5.81E-03 
NM_177624 
sentan, cilia apical structure 
protein Sntn -0.43 6.55E-08 1.41E-05 
NM_001172473 sphingosine kinase 1 Sphk1 0.39 1.69E-04 4.73E-03 
NM_133903 
spondin 2, extracellular matrix 
protein Spon2 -0.46 3.05E-03 3.68E-02 
NM_029688 
sulfiredoxin 1 homolog (S. 
cerevisiae) Srxn1 1.35 2.55E-13 3.81E-10 
NM_019992 
signal transducing adaptor 
family member 1 Stap1 -0.46 4.39E-06 3.25E-04 
NM_020564 
sulfotransferase family 5A, 
member 1 Sult5a1 0.40 8.63E-06 5.40E-04 
NM_138649 synaptotagmin XVII Syt17 0.40 1.49E-04 4.31E-03 
NM_001161832 brachyury 2 T2 -0.50 1.91E-07 3.07E-05 
NM_029464 testis expressed 26 Tex26 -0.39 6.52E-06 4.39E-04 
NM_009363 
trefoil factor 2 (spasmolytic 
protein 1) Tff2 0.62 1.92E-04 5.15E-03 
NM_001145886 
T cell lymphoma invasion and 
metastasis 1 Tiam1 -0.39 7.87E-08 1.63E-05 
NM_001168333 
tubulointerstitial nephritis 
antigen-like 1 Tinagl1 0.41 2.16E-06 1.89E-04 
NM_030682 toll-like receptor 1 Tlr1 -0.40 2.35E-04 5.88E-03 
NM_001008973 transmembrane protein 232 
Tmem23
2 -0.62 4.00E-10 2.20E-07 
NM_021407 
triggering receptor expressed 
on myeloid cells 3 Trem3 -0.50 1.82E-03 2.57E-02 
NM_001033922 
triggering receptor expressed 
on myeloid cells-like 4 Treml4 -0.67 1.14E-06 1.19E-04 
NM_175648 tripartite motif-containing 30B Trim30b -0.62 1.47E-04 4.26E-03 
XR_378392 tripartite motif-containing 30C Trim30c -0.41 4.29E-03 4.62E-02 
NM_001167828 tripartite motif-containing 30D Trim30d -0.41 3.64E-05 1.51E-03 
NM_001168541 tsukushi Tsku 0.74 9.88E-15 2.06E-11 
NM_146173 tetraspanin 33 Tspan33 0.54 1.30E-07 2.31E-05 
NM_138628 taxilin beta Txlnb -0.45 2.33E-03 3.03E-02 
NM_015762 thioredoxin reductase 1 Txnrd1 0.83 4.53E-16 1.42E-12 
NM_011670 
ubiquitin carboxy-terminal 
hydrolase L1 Uchl1 0.66 1.25E-09 5.87E-07 
NM_029770 unc-5 homolog B (C. elegans) Unc5b 0.39 1.86E-06 1.68E-04 
NM_001293561 unc-5 homolog C (C. elegans) Unc5c -0.39 2.82E-05 1.25E-03 
ENSMUST0000
0126637 
WAS/WASL interacting protein 




WD repeat domain, 
phosphoinositide interacting 1 Wipi1 0.40 4.79E-08 1.14E-05 
NM_016873 
WNT1 inducible signaling 
pathway protein 2 Wisp2 -0.45 1.73E-04 4.81E-03 
NM_021394 Z-DNA binding protein 1 Zbp1 -0.50 3.18E-04 7.31E-03 
NM_001033324 
zinc finger and BTB domain 
containing 16 Zbtb16 0.80 2.26E-03 2.99E-02 
NM_178404 
zinc finger CCCH type 
containing 6 Zc3h6 -0.40 2.45E-05 1.14E-03 
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APPENDIX 4: RESULTS FOR ASSOCIATION OF EXPOSURE-RESPONSE GENES WITH 
FOLD CHANGE>1.3 AFTER 5 DAYS OF EXPOSURE.  
This table includes the subset of all significant exposure-response genes with a fold change 
greater than +/-1.3 after 5 days of exposure, with the corresponding b coefficient, p value, and q 
value for association with exposure for each gene.  


















k 0.50 1.25E-06 1.44E-04 
NR_040257 




k 0.42 6.94E-10 3.57E-07 
NR_040725 
RIKEN cDNA 3110039I08 
gene 
311003
9I08Rik -0.43 4.14E-05 2.22E-03 
ENSMUST0000
0044188 




k -0.44 2.17E-06 2.22E-04 
XR_392662 




k 0.45 1.55E-04 5.86E-03 
XR_401960 




k 0.58 4.08E-07 6.04E-05 
ENSMUST0000
0160298 




k -0.39 2.33E-03 4.05E-02 
NM_178796 




k -0.50 1.25E-03 2.66E-02 
NM_175688 




k -0.49 1.33E-05 9.10E-04 
NM_001166556 
ATP-binding cassette, sub-
family A (ABC1), member 6 Abca6 0.46 1.13E-07 2.17E-05 
NM_023732 
ATP-binding cassette, sub-
family B (MDR/TAP), member 
6 Abcb6 0.44 9.94E-10 4.94E-07 
NM_030239 
ATP-binding cassette, sub-
family G (WHITE), member 3 Abcg3 -0.39 7.39E-04 1.84E-02 
NM_001161667 
acyl-Coenzyme A oxidase 2, 
branched chain Acox2 0.59 3.72E-10 2.33E-07 
NM_028765 acyl-Coenzyme A oxidase-like Acoxl -0.54 9.11E-11 8.66E-08 
NM_019807 acid phosphatase, prostate Acpp 0.83 2.35E-14 6.70E-11 
NM_019811 
acyl-CoA synthetase short-
chain family member 2 Acss2 0.47 1.32E-05 9.06E-04 
NM_001291066 
a disintegrin and 
metallopeptidase domain 8 Adam8 0.41 3.06E-04 9.64E-03 
NM_009621 
a disintegrin-like and 
metallopeptidase (reprolysin 
Adamts
1 -0.42 1.56E-07 2.74E-05 
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type) with thrombospondin 
type 1 mo 
NM_175501 
a disintegrin-like and 
metallopeptidase (reprolysin 
type) with thrombospondin 
type 1 mo 
Adamts
12 -0.42 2.59E-04 8.60E-03 
NM_001033877 
a disintegrin-like and 
metallopeptidase (reprolysin 
type) with thrombospondin 
type 1 mo 
Adamts
17 -0.79 1.72E-06 1.85E-04 
ENSMUST0000
0113438 
a disintegrin-like and 
metallopeptidase (reprolysin 
type) with thrombospondin 
type 1 mo 
Adamts
9 -0.42 4.86E-04 1.37E-02 
NM_009626 
alcohol dehydrogenase 7 
(class IV), mu or sigma 
polypeptide Adh7 1.57 7.19E-14 1.73E-10 
NM_011783 anterior gradient 2 Agr2 0.67 2.54E-05 1.51E-03 
NM_001271806 agouti related protein Agrp 0.60 2.87E-10 1.96E-07 
NM_133245 
alpha hemoglobin stabilizing 
protein Ahsp 0.94 3.09E-04 9.70E-03 
ENSMUST0000
0104942 cDNA sequence AK157302 
AK157
302 0.42 1.15E-05 8.06E-04 
ENSMUST0000
0038406 
aldo-keto reductase family 1, 
member B8 Akr1b8 0.58 1.33E-08 4.04E-06 
NM_134072 
aldo-keto reductase family 1, 
member C14 
Akr1c1
4 0.70 4.59E-08 1.04E-05 
NM_001102446 
aminolevulinic acid synthase 
2, erythroid Alas2 0.96 3.51E-10 2.24E-07 
NM_001112725 
aldehyde dehydrogenase 
family 3, subfamily A1 
Aldh3a
1 2.39 9.92E-19 7.77E-15 
NM_001033349 
ankrin repeat and ubiquitin 
domain containing 1 Ankub1 0.50 2.60E-06 2.55E-04 
NM_001161621 
amine oxidase, copper-
containing 1 Aoc1 -0.42 8.98E-07 1.11E-04 
NM_009676 aldehyde oxidase 1 Aox1 0.69 8.14E-14 1.82E-10 
NM_023617 aldehyde oxidase 3 Aox3 0.39 6.32E-10 3.30E-07 
NM_011784 apelin receptor Aplnr -0.74 1.39E-08 4.15E-06 
NM_001143686 apolipoprotein L 11b 
Apol11
b 1.56 1.94E-09 8.56E-07 
NM_175391 apolipoprotein L 7c Apol7c 1.01 6.08E-07 8.33E-05 
NM_009704 amphiregulin Areg -0.42 8.11E-04 1.97E-02 
NM_177828 
Rho guanine nucleotide 
exchange factor (GEF) 37 
Arhgef
37 -0.39 8.73E-05 3.91E-03 
ENSMUST0000
0101044 
ATPase, Ca++ transporting, 
plasma membrane 2 Atp2b2 0.42 6.10E-07 8.33E-05 
NM_134157 
ATPase, H+ transporting, 
lysosomal V1 subunit B1 
Atp6v1





972 0.56 2.88E-09 1.22E-06 
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NM_001037925 cDNA sequence BC147527 
BC147
527 -0.41 1.25E-03 2.66E-02 
NM_007528 
B cell CLL/lymphoma 6, 
member B Bcl6b -0.53 4.07E-06 3.72E-04 
NM_009747 bradykinin receptor, beta 2 Bdkrb2 0.62 1.63E-08 4.72E-06 
ENSMUST0000
0037399 
biliverdin reductase B (flavin 




mutase Bpgm 0.54 5.15E-10 2.98E-07 
NM_011126 
BPI fold containing family A, 
member 1 Bpifa1 0.45 7.25E-04 1.82E-02 
NM_008953 
BPI fold containing family A, 
member 2 Bpifa2 -1.00 8.87E-07 1.10E-04 
NM_026979 
C1q and tumor necrosis factor 
related protein 2 
C1qtnf
2 -0.57 1.15E-06 1.35E-04 
NM_181315 
carbonic anhydrase 5b, 
mitochondrial Car5b 0.42 5.00E-08 1.11E-05 
NM_001080820 
Cas scaffolding protein family 
member 4 Cass4 -0.42 2.18E-05 1.36E-03 
NM_173047 carbonyl reductase 3 Cbr3 1.44 8.69E-16 4.54E-12 
NM_001271353 cystathionine beta-synthase Cbs 0.39 1.94E-04 6.87E-03 
NM_001293560 
cysteine conjugate-beta lyase 
2 Ccbl2 0.50 1.27E-07 2.34E-05 
NM_009915 
chemokine (C-C motif) 
receptor 2 Ccr2 -0.51 2.75E-05 1.61E-03 
NM_009914 
chemokine (C-C motif) 
receptor 3 Ccr3 -0.91 1.64E-03 3.21E-02 
ENSMUST0000
0170878 CD180 antigen Cd180 -0.46 1.39E-03 2.86E-02 
NM_170758 CD300A antigen 
Cd300
a -0.44 1.15E-03 2.51E-02 
NM_172050 CD300e antigen 
Cd300
e -0.46 1.02E-03 2.33E-02 
NM_009866 cadherin 11 Cdh11 -0.39 2.31E-10 1.68E-07 
XM_006544444 
cadherin-related family 
member 4 Cdhr4 0.40 1.82E-09 8.28E-07 
NM_183294 
cyclin-dependent kinase-like 1 
(CDC2-related kinase) Cdkl1 -0.45 5.70E-07 7.93E-05 
NM_030728 
cell migration inducing protein, 
hyaluronan binding Cemip -0.45 8.94E-05 3.97E-03 
NM_144930 carboxylesterase 1F Ces1f 0.84 2.52E-10 1.76E-07 
NM_021456 carboxylesterase 1G Ces1g 2.61 2.32E-17 1.45E-13 
NM_017474 
chloride channel calcium 
activated 3 Clca3 -1.61 2.69E-03 4.43E-02 
NM_139148 
chloride channel calcium 
activated 4 Clca4 0.78 1.11E-04 4.59E-03 
NM_018778 claudin 8 Cldn8 -0.40 4.61E-06 4.09E-04 
NM_009131 
C-type lectin domain family 11, 
member a 
Clec11
a -0.57 8.78E-05 3.92E-03 
NM_177686 
C-type lectin domain family 12, 
member a 
Clec12




C-type lectin domain family 4, 
member a1 
Clec4a
1 -0.53 1.10E-06 1.32E-04 
NM_001204241 
C-type lectin domain family 4, 
member a3 
Clec4a
3 -0.40 2.73E-04 8.89E-03 
NM_007724 
cyclic nucleotide gated 
channel alpha 2 Cnga2 0.78 2.76E-08 7.04E-06 
NM_009930 collagen, type III, alpha 1 Col3a1 -0.58 7.38E-04 1.84E-02 
NM_001243008 collagen, type VI, alpha 3 Col6a3 -0.45 1.53E-05 1.01E-03 
XM_006519193 
collagen-like tail subunit 
(single strand of homotrimer) 
of asymmetric acetylcholineste Colq -0.43 1.54E-04 5.82E-03 
NR_002845 
coatomer protein complex, 
subunit gamma 2, opposite 
strand 2 
Copg2
os2 0.42 2.09E-05 1.31E-03 
NM_007771 
cryptochrome 1 (photolyase-
like) Cry1 0.95 3.13E-14 8.18E-11 
NM_007799 cathepsin E Ctse 0.48 2.02E-05 1.28E-03 
NM_009987 
chemokine (C-X3-C motif) 
receptor 1 Cx3cr1 -0.49 9.83E-06 7.16E-04 
NM_021274 
chemokine (C-X-C motif) 
ligand 10 Cxcl10 -0.45 1.06E-04 4.45E-03 
NM_153576 
chemokine (C-X-C motif) 
ligand 17 Cxcl17 0.55 3.42E-09 1.38E-06 
NM_178241 
chemokine (C-X-C motif) 
receptor 1 Cxcr1 1.07 2.24E-04 7.67E-03 
NM_001136059 
cytochrome P450, family 1, 
subfamily a, polypeptide 1 Cyp1a1 4.59 2.98E-24 4.67E-20 
NM_009994 
cytochrome P450, family 1, 
subfamily b, polypeptide 1 Cyp1b1 3.01 1.42E-27 4.47E-23 
NM_009997 
cytochrome P450, family 2, 
subfamily a, polypeptide 4 Cyp2a4 0.63 9.58E-05 4.14E-03 
ENSMUST0000
0005685 
cytochrome P450, family 2, 
subfamily a, polypeptide 5 Cyp2a5 0.50 4.54E-04 1.30E-02 
NM_001163472 
cytochrome P450, family 2, 
subfamily d, polypeptide 22 
Cyp2d2
2 0.40 1.67E-04 6.15E-03 
NM_007819 
cytochrome P450, family 3, 
subfamily a, polypeptide 13 
Cyp3a1
3 0.66 1.63E-06 1.77E-04 
NR_033575 
cytochrome P450, family 4, 
subfamily b, polypeptide 1, 
pseudogene 2 
Cyp4b1
-ps2 0.77 2.46E-05 1.49E-03 
NM_001004455 cystin 1 Cys1 0.51 5.84E-05 2.87E-03 
NM_177564 
dehydrogenase/reductase 
(SDR family) member 11 Dhrs11 0.46 3.64E-09 1.43E-06 
NM_013811 
dynein, axonemal, heavy chain 
8 Dnah8 -0.40 7.88E-05 3.61E-03 
NM_008748 dual specificity phosphatase 8 Dusp8 -0.40 1.16E-06 1.36E-04 
NR_015502 




k 0.54 4.07E-05 2.20E-03 
NM_007895 
eosinophil-associated, 
ribonuclease A family, member 





ribonuclease A family, member 
7 Ear7 1.22 3.36E-04 1.04E-02 
NM_010104 endothelin 1 Edn1 0.56 1.22E-06 1.41E-04 
AK002956 
endogenous sequence related 
to the Duplan murine retrovirus Edv 0.50 6.54E-08 1.36E-05 
NM_025499 
EP300 interacting inhibitor of 
differentiation 3 Eid3 0.48 7.33E-06 5.79E-04 
NM_001163131 E74-like factor 3 Elf3 0.42 9.63E-06 7.07E-04 
NM_139138 
EGF-like module containing, 
mucin-like, hormone receptor-
like sequence 4 Emr4 -1.05 4.34E-08 9.94E-06 
NM_001026214 
ectonucleoside triphosphate 
diphosphohydrolase 5 Entpd5 0.56 1.69E-10 1.39E-07 
NM_001128606 erythrocyte protein band 4.1 Epb4.1 0.47 1.30E-10 1.14E-07 
ENSMUST0000
0102490 erythrocyte protein band 4.2 Epb4.2 0.46 7.61E-07 9.70E-05 
NM_029325 epididymal peptidase inhibitor Eppin 0.47 2.12E-03 3.80E-02 
ENSMUST0000
0098496 glutamate rich 3 Erich3 0.69 5.38E-09 1.85E-06 
ENSMUST0000
0172865 glutamate rich 3 Erich3 0.63 1.17E-08 3.68E-06 
NR_033558 




k 0.40 2.98E-04 9.45E-03 
NM_017399 
fatty acid binding protein 1, 
liver Fabp1 -1.13 3.44E-09 1.38E-06 
NM_183187 
family with sequence similarity 
107, member A 
Fam10
7a 0.78 3.47E-04 1.06E-02 
NM_173425 
family with sequence similarity 
124, member B 
Fam12
4b -0.39 2.27E-05 1.41E-03 
ENSMUST0000
0153830 
family with sequence similarity 
213, member A 
Fam21
3a 0.48 6.15E-06 5.09E-04 
NM_026050 
family with sequence similarity 
220, member A 
Fam22
0a 0.54 5.06E-09 1.79E-06 
NM_001142952 
family with sequence similarity 
46, member C 
Fam46
c 0.69 5.68E-12 8.14E-09 
NM_001080814 
FAT tumor suppressor 
homolog 3 (Drosophila) Fat3 -0.58 7.32E-07 9.45E-05 
NM_010186 Fc receptor, IgG, high affinity I Fcgr1 -0.51 5.79E-06 4.92E-04 
NM_007998 ferrochelatase Fech 0.62 9.21E-14 1.92E-10 
XM_006543235 fer-1-like 6 (C. elegans) Fer1l6 -0.60 6.95E-04 1.76E-02 
NM_001271616 
fibroblast growth factor binding 
protein 1 Fgfbp1 0.95 1.24E-09 5.89E-07 
NM_008011 
fibroblast growth factor 
receptor 4 Fgfr4 -0.53 7.87E-07 9.95E-05 
NM_010220 FK506 binding protein 5 Fkbp5 0.76 6.99E-04 1.76E-02 
NM_001081185 filamin C, gamma Flnc 0.45 3.68E-04 1.11E-02 
NM_144878 
flavin containing 




0134311 FBJ osteosarcoma oncogene Fos -0.47 9.49E-04 2.20E-02 
NM_008046 follistatin Fst 0.60 1.18E-04 4.82E-03 







5 1.05 1.86E-07 3.22E-05 
NM_010295 
glutamate-cysteine ligase, 
catalytic subunit Gclc 0.40 8.80E-06 6.61E-04 
NM_008129 
glutamate-cysteine ligase, 




containing 2 Gdpd2 0.42 2.43E-03 4.15E-02 
NM_008115 
glial cell line derived 
neurotrophic factor family 
receptor alpha 2 Gfra2 -0.87 5.35E-11 5.79E-08 
AK136967 predicted gene 10808 
Gm108
08 -0.46 9.67E-06 7.08E-04 
XR_392652 predicted gene 10931 
Gm109
31 0.53 1.55E-04 5.85E-03 
XR_406739 predicted gene 11783 
Gm117
83 -0.43 3.19E-04 9.98E-03 
ENSMUST0000
0143311 predicted gene 12022 
Gm120
22 -0.39 3.45E-05 1.92E-03 
ENSMUST0000
0144765 predicted gene 12395 
Gm123
95 0.48 1.55E-04 5.85E-03 
ENSMUST0000
0141375 predicted gene 13307 
Gm133
07 0.43 5.57E-04 1.51E-02 
ENSMUST0000
0159142 predicted gene 15889 
Gm158
89 0.91 6.94E-07 9.14E-05 
XM_006497081 predicted gene 16340 
Gm163
40 -0.57 4.30E-05 2.28E-03 
ENSMUST0000
0168078 predicted gene 17046 
Gm170
46 0.59 8.10E-04 1.97E-02 
XR_400197 predicted gene, 19501 
Gm195
01 -0.43 4.16E-04 1.22E-02 
NM_001277183 predicted gene 1966 
Gm196
6 -0.41 9.46E-05 4.12E-03 
XR_378466 predicted gene, 19950 
Gm199
50 0.52 5.22E-06 4.49E-04 
ENSMUST0000
0174884 predicted gene 20475 
Gm204
75 -0.39 1.73E-04 6.32E-03 
AK172267 predicted gene, 21188 
Gm211
88 -0.42 3.24E-04 1.01E-02 
ENSMUST0000
0157550 predicted gene, 23101 
Gm231
01 -0.65 6.15E-05 3.00E-03 
ENSMUST0000
0158661 predicted gene, 24277 
Gm242
77 -0.40 1.51E-04 5.75E-03 
NM_001243092 predicted gene 3776 
Gm377
6 1.06 1.31E-10 1.14E-07 
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NR_002858 predicted gene 4956 
Gm495
6 0.43 5.23E-06 4.49E-04 
ENSMUST0000
0108347 predicted gene 5150 
Gm515
0 -0.46 4.24E-04 1.24E-02 
XR_387506 predicted gene 5532 
Gm553
2 0.43 4.09E-04 1.20E-02 
AK041157 predicted pseudogene 5859 
Gm585
9 0.45 1.68E-04 6.20E-03 
NR_033643 ubiquitin-like 5 pseudogene 
Gm664
2 -0.51 7.26E-05 3.39E-03 
ENSMUST0000
0095071 predicted gene 8074 
Gm807
4 0.55 2.95E-08 7.40E-06 
XR_378400 predicted gene 8995 
Gm899
5 -0.40 7.69E-06 5.97E-04 
NM_001076679 predicted gene 9733 
Gm973
3 -0.79 9.17E-07 1.13E-04 
NM_025989 
glycoprotein 2 (zymogen 
granule membrane) Gp2 0.48 1.65E-03 3.21E-02 
NM_027518 
G protein-coupled receptor 
137C 
Gpr137
c 0.57 9.72E-08 1.89E-05 
NM_181754 
G protein-coupled receptor 
141 Gpr141 -0.42 5.40E-04 1.48E-02 
NM_178406 
G protein-coupled receptor 
153 Gpr153 -0.41 2.34E-08 6.17E-06 
NM_008159 G protein-coupled receptor 33 Gpr33 -0.39 3.73E-04 1.12E-02 
NM_008152 G-protein coupled receptor 65 Gpr65 -0.42 1.16E-03 2.53E-02 
NM_008181 
glutathione S-transferase, 
alpha 1 (Ya) Gsta1 0.58 1.27E-04 5.08E-03 
NM_001077353 
glutathione S-transferase, 
alpha 3 Gsta3 0.82 1.55E-10 1.31E-07 
NM_010357 
glutathione S-transferase, 
alpha 4 Gsta4 0.52 6.21E-10 3.30E-07 
NM_010362 
glutathione S-transferase 
omega 1 Gsto1 0.49 6.00E-10 3.25E-07 
NM_013541 glutathione S-transferase, pi 1 Gstp1 0.41 1.97E-08 5.33E-06 
NM_181796 glutathione S-transferase, pi 2 Gstp2 0.48 1.73E-11 2.17E-08 
NM_013755 glycogenin Gyg -0.43 2.44E-07 4.03E-05 
NM_010369 glycophorin A Gypa 1.46 3.23E-09 1.35E-06 
AK157055 
hemoglobin, beta adult minor 
chain Hbb-b2 0.66 5.29E-08 1.15E-05 
ENSMUST0000
0023934 hemoglobin, beta adult t chain Hbb-bt 0.65 2.53E-06 2.51E-04 
ENSMUST0000
0098192 hemoglobin, beta adult t chain Hbb-bt 0.97 3.78E-09 1.46E-06 
NM_008230 histidine decarboxylase Hdc -0.85 1.38E-07 2.47E-05 
NM_178899 HEPACAM family member 2 
Hepaca
m2 -0.49 1.70E-05 1.11E-03 
NM_001024720 hemicentin 1 Hmcn1 -0.45 5.44E-10 2.99E-07 
NM_013868 
heat shock protein family, 








k -0.66 2.57E-05 1.52E-03 
NM_001045481 interferon activated gene 203 Ifi203 -0.40 7.79E-05 3.58E-03 
NM_008328 interferon activated gene 203 Ifi203 -0.42 2.17E-04 7.48E-03 
NM_008329 interferon activated gene 204 Ifi204 -0.77 9.20E-05 4.03E-03 
NM_029803 
interferon, alpha-inducible 
protein 27 like 2A Ifi27l2a -0.41 2.19E-03 3.88E-02 
NM_133871 interferon-induced protein 44 Ifi44 -0.49 9.44E-04 2.18E-02 
NM_001033632 
interferon induced 
transmembrane protein 6 Ifitm6 -0.87 3.48E-08 8.33E-06 
ENSMUST0000
0103485 
immunoglobulin heavy variable 
V12-3 
Ighv12-
3 -1.08 1.80E-03 3.42E-02 
ENSMUST0000
0103324 
immunoglobulin kappa chain 
variable 15-103 
Igkv15-






80 -1.02 1.44E-03 2.92E-02 
NM_001162884 
immunoglobulin superfamily, 
member 10 Igsf10 -0.65 1.31E-04 5.18E-03 
NM_030691 
immunoglobulin superfamily, 
member 6 Igsf6 -0.43 4.10E-04 1.20E-02 
NM_008348 interleukin 10 receptor, alpha Il10ra -0.42 3.10E-05 1.78E-03 
NM_008361 interleukin 1 beta Il1b -0.62 1.04E-03 2.34E-02 
NM_001253872 integrin alpha L Itgal -0.40 5.88E-06 4.96E-04 
NM_001082960 integrin alpha M Itgam -0.43 2.61E-03 4.34E-02 
NM_001164268 kalirin, RhoGEF kinase Kalrn 0.54 1.79E-08 5.02E-06 
NM_021342 
potassium voltage-gated 
channel, Isk-related subfamily, 
gene 4 Kcne4 -0.42 3.80E-04 1.14E-02 
NM_134090 
KDEL (Lys-Asp-Glu-Leu) 
endoplasmic reticulum protein 
retention receptor 3 Kdelr3 -0.52 2.37E-05 1.44E-03 
NM_001170851 
killer cell lectin-like receptor, 
subfamily A, member 2 Klra2 -0.47 9.07E-07 1.12E-04 
NM_001012520 
killer cell lectin-like receptor 
family I member 1 Klri1 -0.42 1.90E-03 3.55E-02 
NM_008469 keratin 15 Krt15 0.85 5.16E-05 2.60E-03 
NM_008471 keratin 19 Krt19 0.39 8.76E-09 2.86E-06 
NM_011836 laminin gamma 3 Lamc3 0.43 2.38E-03 4.09E-02 


















3 -0.64 4.44E-07 6.42E-05 
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XR_386789 uncharacterized LOC73899 
LOC73
899 -0.42 2.48E-03 4.19E-02 
NM_028894 
LON peptidase N-terminal 
domain and ring finger 3 Lonrf3 0.61 4.78E-09 1.75E-06 
NM_001286181 lysyl oxidase Lox 0.59 5.14E-08 1.13E-05 




acyltransferase) Lrat -0.51 2.81E-03 4.56E-02 
NM_146242 
leucine rich repeat containing 
10 Lrrc10 0.54 1.76E-04 6.39E-03 
NM_001271708 
leucine rich repeat protein 3, 
neuronal Lrrn3 0.44 1.66E-04 6.15E-03 
NM_001172207 
leucine-rich repeats and 
transmembrane domains 2 Lrtm2 0.60 3.56E-07 5.40E-05 
NM_010734 leukocyte specific transcript 1 Lst1 -0.50 9.49E-07 1.15E-04 
NM_010745 lymphocyte antigen 86 Ly86 -0.48 4.07E-05 2.20E-03 
NM_027990 
LY6/PLAUR domain 
containing 6B Lypd6b 0.39 7.78E-06 6.03E-04 
NM_053247 
lymphatic vessel endothelial 
hyaluronan receptor 1 Lyve1 0.61 3.93E-09 1.48E-06 
NM_010755 
v-maf musculoaponeurotic 
fibrosarcoma oncogene family, 
protein F (avian) Maff 0.49 1.51E-07 2.67E-05 
NM_145532 
mal, T cell differentiation 
protein-like Mall 0.46 1.21E-07 2.29E-05 
NM_016693 
mitogen-activated protein 
kinase kinase kinase 6 
Map3k
6 0.72 1.63E-04 6.10E-03 
NM_030174 
multiple C2 domains, 
transmembrane 1 Mctp1 0.43 3.91E-07 5.90E-05 
NM_001161790 Mediterranean fever Mefv -0.49 9.00E-05 3.98E-03 
NM_029568 
microfibrillar-associated 




lectin 2 Mgl2 -0.43 2.17E-03 3.85E-02 
NR_030559 microRNA 453 Mir453 -0.39 4.07E-04 1.20E-02 
NR_039563 microRNA 5104 
Mir510
4 -0.42 1.64E-03 3.21E-02 
NR_030464 microRNA 691 Mir691 -0.38 1.98E-03 3.65E-02 
NM_001033450 
myeloid cell nuclear 
differentiation antigen Mnda -0.54 1.68E-05 1.10E-03 
NM_008626 mannose receptor, C type 2 Mrc2 -0.59 4.63E-09 1.73E-06 
XM_006527251 
membrane-spanning 4-
domains, subfamily A, member 
4C 
Ms4a4
c -0.60 1.82E-06 1.94E-04 
NM_028595 
membrane-spanning 4-
domains, subfamily A, member 
6C 
Ms4a6
c -0.46 1.37E-05 9.28E-04 
NM_013602 metallothionein 1 Mt1 0.39 1.22E-06 1.41E-04 
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NM_008630 metallothionein 2 Mt2 0.67 3.41E-07 5.21E-05 
NM_010846 
myxovirus (influenza virus) 
resistance 1 Mx1 -0.47 6.10E-04 1.61E-02 
NM_001083934 myomesin 1 Myom1 0.42 7.53E-04 1.87E-02 
NM_001145959 
N-myc downstream regulated 
gene 2 Ndrg2 0.41 3.88E-06 3.60E-04 
NR_027858 
NLR family, pyrin domain 
containing 1C, pseudogene 
Nlrp1c-
ps -0.53 8.96E-05 3.97E-03 
NM_001291128 neuronatin Nnat -0.47 6.04E-06 5.01E-04 
NM_008719 
neuronal PAS domain protein 
2 Npas2 -0.46 4.93E-04 1.38E-02 
NM_008706 
NAD(P)H dehydrogenase, 
quinone 1 Nqo1 2.64 1.46E-22 1.53E-18 
NM_145434 
nuclear receptor subfamily 1, 
group D, member 1 Nr1d1 -0.53 2.49E-06 2.48E-04 
NM_010444 
nuclear receptor subfamily 4, 
group A, member 1 Nr4a1 -0.70 2.16E-05 1.35E-03 
NM_001146031 
neuron-glia-CAM-related cell 
adhesion molecule Nrcam -0.62 1.95E-06 2.04E-04 
NM_001109989 
neuronal regeneration related 
protein Nrep -0.66 1.72E-06 1.85E-04 
NM_172921 
neurexophilin and PC-esterase 
domain family, member 4 Nxpe4 -0.55 1.25E-07 2.34E-05 
NM_145211 
2-5 oligoadenylate synthetase 
1A Oas1a -0.52 1.39E-04 5.39E-03 
NM_145227 
2-5 oligoadenylate synthetase 
2 Oas2 -0.65 6.37E-06 5.20E-04 
BC119161 olfactory receptor 1342 
Olfr134
2 -0.46 9.49E-05 4.12E-03 
NM_013623 orosomucoid 3 Orm3 0.39 1.54E-03 3.06E-02 
NM_027950 
oxidative stress induced 
growth inhibitor 1 Osgin1 0.60 1.09E-13 2.13E-10 
NM_017378 protocadherin 12 Pcdh12 -0.62 7.66E-07 9.72E-05 
NM_011057 
platelet derived growth factor, 
B polypeptide Pdgfb -0.42 4.63E-06 4.10E-04 
NM_011066 period circadian clock 2 Per2 0.73 2.18E-09 9.48E-07 
NM_022032 
PERP, TP53 apoptosis 
effector Perp 0.40 1.11E-06 1.32E-04 
NM_001081274 
phosphogluconate 
dehydrogenase Pgd 0.40 4.88E-09 1.76E-06 
NM_001164327 PHD finger protein 11B Phf11b -0.53 5.93E-06 4.98E-04 
NM_001039485 
piezo-type mechanosensitive 
ion channel component 2 Piezo2 -0.57 2.37E-11 2.75E-08 
BC172053 
paired immunoglobin-like type 
2 receptor beta 1 Pilrb1 -0.55 4.73E-04 1.34E-02 
ENSMUST0000
0031264 placenta-specific 8 Plac8 -0.75 1.12E-06 1.32E-04 
NM_025806 
phospholipase B domain 
containing 1 Plbd1 -0.48 6.04E-08 1.27E-05 




phospholipase D family, 
member 4 Pld4 -0.52 6.14E-08 1.28E-05 
NM_001160268 
pleckstrin homology domain 
containing, family A member 6 
Plekha
6 -0.43 7.52E-05 3.48E-03 
NM_026376 plexin D1 Plxnd1 -0.43 2.01E-07 3.43E-05 
NM_026784 phosphomevalonate kinase Pmvk 0.67 5.97E-09 2.03E-06 
NM_080464 
protein phosphatase 1, 
regulatory (inhibitor) subunit 
3A 
Ppp1r3
a 0.41 2.32E-03 4.04E-02 
NM_029947 PR domain containing 8 Prdm8 -0.63 8.16E-04 1.98E-02 
NM_008855 protein kinase C, beta Prkcb -0.40 1.99E-03 3.65E-02 
NM_178738 protease, serine 35 Prss35 -0.47 9.18E-04 2.15E-02 
NM_011198 
prostaglandin-endoperoxide 
synthase 2 Ptgs2 0.64 1.16E-07 2.23E-05 
NM_025831 PX domain containing 1 Pxdc1 0.46 9.21E-07 1.13E-04 
NM_001002786 
RAB44, member RAS 
oncogene family Rab44 -0.51 1.58E-03 3.12E-02 
NM_009026 
RAS, dexamethasone-induced 
1 Rasd1 0.50 1.32E-03 2.76E-02 
NM_001166493 
RAS, guanyl releasing protein 
3 
Rasgrp
3 -0.43 1.50E-04 5.71E-03 
NM_001174155 
RAS guanyl releasing protein 
4 
Rasgrp
4 -0.39 5.79E-05 2.85E-03 
NM_011260 
regenerating islet-derived 3 
gamma Reg3g 0.48 1.43E-04 5.49E-03 
NM_011261 reelin Reln 0.43 1.31E-06 1.48E-04 
BC038337 regulator of cell cycle Rgcc 0.44 1.04E-04 4.39E-03 
NM_025427 regulator of cell cycle Rgcc 0.51 2.59E-05 1.53E-03 
NM_030098 
ribonuclease, RNase A family, 
6 Rnase6 -0.41 1.34E-04 5.27E-03 
NM_001293734 
RAR-related orphan receptor 
gamma Rorc 0.79 1.90E-09 8.51E-07 
ENSMUST0000
0137792 
radical S-adenosyl methionine 
domain containing 2 Rsad2 0.74 5.33E-08 1.15E-05 
NM_054037 
secretoglobin, family 3A, 
member 1 
Scgb3a
1 0.59 9.49E-13 1.57E-09 
NM_018732 
sodium channel, voltage-
gated, type III, alpha Scn3a -0.59 1.52E-06 1.67E-04 
NM_001083917 
sodium channel, voltage-
gated, type III, beta Scn3b -0.86 7.91E-08 1.58E-05 
NM_009136 scrapie responsive gene 1 Scrg1 -0.42 9.18E-05 4.03E-03 
NM_020052 
signal peptide, CUB domain, 
EGF-like 2 Scube2 -0.38 2.90E-04 9.27E-03 
ENSMUST0000
0090839 selenium binding protein 1 
Selenb
p1 0.90 2.87E-15 1.13E-11 
NM_019414 selenium binding protein 2 
Selenb
p2 0.63 5.25E-10 2.98E-07 
NM_009253 
serine (or cysteine) peptidase 
inhibitor, clade A, member 3M 
Serpina




serine (or cysteine) peptidase 
inhibitor, clade B (ovalbumin), 
member 10 
Serpinb
10 -0.81 8.82E-06 6.62E-04 
NM_001111043 
serine (or cysteine) peptidase 
inhibitor, clade H, member 1 
Serpinh
1 -0.41 7.43E-06 5.83E-04 
NM_001162533 SH3 domain containing 21 Sh3d21 0.40 1.26E-04 5.07E-03 
NM_178706 
sialic acid binding Ig-like lectin 
H Siglech -0.38 6.43E-04 1.66E-02 
NM_029084 SLAM family member 8 Slamf8 -0.41 1.39E-03 2.86E-02 
NM_022411 





2 0.41 2.37E-05 1.44E-03 
NM_172892 




4 0.43 2.32E-05 1.43E-03 
NM_011395 
solute carrier family 22 
(organic cation transporter), 
member 3 
Slc22a
3 -0.65 3.06E-08 7.55E-06 
NM_026331 
solute carrier family 25, 
member 37 
Slc25a
37 0.80 6.29E-15 1.97E-11 
NM_177615 
solute carrier family 26, 
member 10 
Slc26a
10 -0.52 9.15E-06 6.77E-04 
ENSMUST0000
0141837 
solute carrier family 2 
(facilitated glucose 
transporter), member 4 Slc2a4 0.52 2.16E-03 3.84E-02 
NM_027052 
solute carrier family 38, 
member 4 
Slc38a
4 0.41 1.08E-03 2.41E-02 
NM_172479 
solute carrier family 38, 
member 5 
Slc38a
5 -0.61 3.49E-06 3.31E-04 
NM_001039676 
solute carrier family 39 (zinc 
transporter), member 2 
Slc39a
2 0.54 2.42E-03 4.14E-02 
NM_027872 
solute carrier family 46, 
member 3 
Slc46a
3 0.55 2.39E-10 1.71E-07 
NM_011403 
solute carrier family 4 (anion 
exchanger), member 1 Slc4a1 1.89 8.75E-11 8.58E-08 
NM_001003915 
solute carrier family 5 
(sodium/glucose 
cotransporter), member 12 
Slc5a1
2 -0.38 3.70E-04 1.11E-02 
NM_017394 
solute carrier family 7 (cationic 
amino acid transporter, y+ 
system), member 10 
Slc7a1
0 -0.76 3.97E-07 5.93E-05 
NM_011990 
solute carrier family 7 (cationic 
amino acid transporter, y+ 
system), member 11 
Slc7a1
1 1.69 1.60E-08 4.68E-06 
NM_011407 schlafen 1 Slfn1 -0.58 2.90E-07 4.62E-05 
NM_011410 schlafen 4 Slfn4 -0.81 6.88E-06 5.52E-04 
NM_001042451 synuclein, alpha Snca 0.90 1.43E-11 1.95E-08 
NM_001172473 sphingosine kinase 1 Sphk1 0.42 1.02E-03 2.33E-02 
NM_133903 
spondin 2, extracellular matrix 




0090872 small proline-rich protein 2A2 
Sprr2a
2 -0.53 2.71E-03 4.45E-02 
NM_011465 spectrin alpha, erythrocytic 1 Spta1 0.82 2.09E-10 1.56E-07 
ENSMUST0000
0166101 spectrin beta, erythrocytic Sptb 0.44 1.89E-04 6.75E-03 
NM_001164210 
serine palmitoyltransferase, 
small subunit B Sptssb 0.45 6.01E-06 5.00E-04 
NM_175347 sarcalumenin Srl 0.53 2.08E-03 3.77E-02 
NM_029688 
sulfiredoxin 1 homolog (S. 







ac3 -0.64 7.10E-11 7.18E-08 
NM_001290728 synaptotagmin-like 5 Sytl5 0.63 2.84E-07 4.57E-05 
NM_011545 transcription factor 21 Tcf21 -0.38 2.25E-07 3.74E-05 
NM_013691 thrombospondin 3 Thbs3 -0.42 1.51E-05 1.00E-03 
NM_001145886 
T cell lymphoma invasion and 
metastasis 1 Tiam1 -0.41 6.14E-07 8.33E-05 
NM_001168333 
tubulointerstitial nephritis 
antigen-like 1 Tinagl1 0.48 2.51E-07 4.12E-05 
NM_031178 toll-like receptor 9 Tlr9 -0.42 1.19E-04 4.84E-03 
NM_001105252 
transmembrane channel-like 
gene family 5 Tmc5 0.69 2.76E-08 7.04E-06 
ENSMUST0000
0067853 transmembrane protein 119 
Tmem1
19 -0.46 6.65E-08 1.37E-05 
NM_175432 transmembrane protein 132C 
Tmem1
32c -0.58 2.48E-11 2.78E-08 
NM_177371 
tumor necrosis factor (ligand) 
superfamily, member 15 Tnfsf15 -0.61 1.29E-06 1.47E-04 
NM_001130174 troponin T2, cardiac Tnnt2 0.40 1.99E-03 3.65E-02 
NM_001033922 
triggering receptor expressed 
on myeloid cells-like 4 Treml4 -0.73 2.59E-08 6.71E-06 
NM_011280 tripartite motif-containing 10 Trim10 0.58 1.22E-06 1.41E-04 
NM_175648 tripartite motif-containing 30B 
Trim30
b -0.42 1.70E-03 3.28E-02 
NM_177374 tRNA methyltransferase 61A 
Trmt61
a -0.38 1.55E-06 1.70E-04 
NM_001168541 tsukushi Tsku 0.80 2.94E-13 5.13E-10 
NM_177709 tumor suppressor candidate 5 Tusc5 0.41 8.28E-06 6.29E-04 
NM_015762 thioredoxin reductase 1 Txnrd1 0.60 5.40E-15 1.88E-11 
NM_173755 
ubiquitin-conjugating enzyme 
E2O Ube2o 0.64 1.16E-13 2.13E-10 
NM_016808 ubiquitin specific peptidase 2 Usp2 0.51 1.42E-07 2.52E-05 
NM_011979 vanin 3 Vnn3 0.40 1.18E-04 4.81E-03 
NM_001080550 
WAP four-disulfide core 
domain 8 Wfdc8 0.58 2.31E-04 7.89E-03 
NM_011798 chemokine (C motif) receptor 1 Xcr1 -0.38 3.14E-04 9.83E-03 
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APPENDIX 5: EXPOSURE-RESPONSE GENES WITH A SIGNIFICANT DURATION-
DEPENDENT RESPONSE.  
This table includes the subset of all exposure-response genes significant at 1 and/or 5 days which 
were also significant (q<0.05) for a post-hoc interaction test between exposure and exposure 
duration. The table includes the B coefficient and p value for exposure at each exposure duration 
and the q value of the interaction. All genes with q<0.05 for the interaction test are included. 
These genes were then put into GSEA’s overlap tool to assess for enrichment in any Canonical 
Pathways. 
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(class IV), mu or 








receptor repressor Ahrr 0.47 1.22E-06 0.15 3.46E-02 3.34E-03 
NM_0010
33349 
ankrin repeat and 
ubiquitin domain 




3 Aox3 0.15 1.08E-02 0.39 3.30E-07 9.88E-03 
NM_0117




11b Apol11b 0.43 4.67E-01 1.56 8.56E-07 2.06E-02 
NM_0097
04 amphiregulin Areg 0.19 4.76E-01 -0.42 1.97E-02 2.03E-02 
NM_0012
84192 artemin Artn 0.78 3.41E-06 0.20 1.38E-02 2.51E-03 
NM_1537
78 
atonal homolog 8 






















receptor, beta 1 Bdkrb1 0.58 8.43E-04 0.09 7.29E-01 3.00E-02 
NM_0089
53 
BPI fold containing 
family A, member 




component 1, r 
subcomponent-
































3 Clca3 1.15 1.95E-01 -1.61 4.43E-02 3.74E-02 
NM_0099
30 
collagen, type III, 
alpha 1 Col3a1 0.15 4.15E-01 -0.58 1.84E-02 1.18E-02 
NM_0012
43008 
collagen, type VI, 












family 3, subfamily 




family 4, subfamily 




family 4, subfamily 






























differentiation 3 Eid3 0.85 1.01E-07 0.48 5.79E-04 3.00E-02 
NM_0079
25 elastin Eln 0.54 5.57E-03 -0.39 6.59E-02 7.65E-03 
NM_0173
99 
fatty acid binding 



















rich repeat protein 
13 Fbxl13 -0.44 7.26E-05 0.00 9.99E-01 3.21E-03 
NM_0079
98 ferrochelatase Fech 0.15 4.70E-01 0.62 1.92E-10 8.63E-03 
NM_1817
48 
free fatty acid 




factor receptor 4 Fgfr4 -0.11 4.80E-01 -0.53 9.95E-05 5.74E-03 
NM_0102
35 fos-like antigen 1 Fosl1 0.57 8.09E-03 -0.03 8.70E-01 6.95E-03 
NM_1770










modifier subunit Gclm 1.19 5.56E-18 0.79 7.35E-12 1.29E-03 
NM_0012
85457 








protein, beta 2 Gjb2 0.89 1.96E-06 0.20 2.91E-01 1.41E-03 
AK136967 
predicted gene 




























































































(decycling) 1 Hmox1 1.76 2.24E-11 0.24 3.85E-01 5.25E-05 
NM_0104
78 
heat shock protein 










member 10 Igsf10 0.07 7.94E-01 -0.65 5.18E-03 5.08E-03 
NM_1728
72 
KN motif and 
ankyrin repeat 




















killer cell lectin-like 
receptor family I 
member 1 Klri1 0.07 8.29E-01 -0.42 3.55E-02 4.12E-02 
NM_0084










Ig heavy chain V 
region 
LOC2384





and ring finger 3 Lonrf3 0.31 4.98E-03 0.61 1.75E-06 4.76E-02 
NM_0107








receptor Lrp8 0.72 3.11E-06 0.16 3.98E-01 4.61E-03 
NM_1461
17 
leucine rich repeat 
















4 Mfap4 0.28 7.44E-02 -0.63 1.95E-03 8.15E-04 
NR_0295




C type 2 Mrc2 -0.03 8.27E-01 -0.59 1.73E-06 9.29E-04 
NM_0011
45874 mucin 20 Muc20 -0.43 3.20E-04 -0.01 9.72E-01 2.51E-03 
NM_0108
92 
NIMA (never in 
mitosis gene a)-
related expressed 
kinase 2 Nek2 -0.46 2.82E-04 -0.11 3.79E-01 4.35E-02 
NM_0012









subfamily 1, group 

















724 Olfr724 0.48 2.87E-03 -0.11 7.54E-01 6.17E-03 
NM_0136





inhibitor 1 Osgin1 1.02 6.29E-11 0.60 2.13E-10 1.42E-02 
NM_0173




growth factor, B 






























































family 3A, member 


















inhibitor, clade H, 
member 1 Serpinh1 -0.10 3.35E-01 -0.41 5.83E-04 1.38E-02 
NM_0091



















family 25, member 





family 2 (facilitated 
glucose 
transporter), 




family 38, member 




family 46, member 




family 4 (anion 
exchanger), 
























member 1a5 Slco1a5 -0.39 2.98E-04 0.14 4.35E-01 2.96E-03 
NM_1776
24 
sentan, cilia apical 




























5 Sytl5 -0.04 8.69E-01 0.63 4.57E-05 1.46E-03 
NM_0011




26 Tex26 -0.39 4.39E-04 0.23 1.05E-01 2.26E-04 
NM_0136




















cardiac Tnnt2 -0.10 5.17E-01 0.40 3.65E-02 1.56E-02 
NM_1386









L1 Uchl1 0.66 5.87E-07 0.34 2.30E-03 2.94E-02 
NM_0119










motif) receptor 1 Xcr1 0.05 8.49E-01 -0.38 9.83E-03 4.89E-02 
NM_1784
04 
zinc finger CCCH 
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